<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004990" GROUP_ID="DEMENTIA" ID="473104042915300760" MERGED_FROM="" MODIFIED="2008-05-14 10:48:00 +0200" MODIFIED_BY="Helen Collins" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.8" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2008-05-14 10:48:00 +0200" MODIFIED_BY="Helen Collins">
<TITLE>Trazodone for agitation in dementia</TITLE>
<CONTACT MODIFIED="2008-05-14 10:48:00 +0200" MODIFIED_BY="Helen Collins"><PERSON ID="7556" ROLE="AUTHOR"><PREFIX>Sir</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Grimley Evans</LAST_NAME><POSITION>Professor Emeritus</POSITION><EMAIL_1>john.grimleyevans@green.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Clinical Geratology, Nuffield Department of Clinical Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Infirmary</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6HE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><FAX_1>+44 1865 224815</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-05-14 10:48:00 +0200" MODIFIED_BY="Helen Collins"><PERSON ID="19496" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Georgina</FIRST_NAME><LAST_NAME>Martinón-Torres</LAST_NAME><POSITION>Specialist Registrar in Geriatric Medicine</POSITION><EMAIL_1>georginamt@vodafone.es</EMAIL_1><EMAIL_2>georginamartinont@hotmail.com</EMAIL_2><ADDRESS><ORGANISATION>Complejo Hospitalario de Ciudad Real</ORGANISATION><ADDRESS_1>Hospital del Carmen</ADDRESS_1><ADDRESS_2>Ronda del Carmen s/n</ADDRESS_2><CITY>Ciudad Real</CITY><ZIP>13002</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 925 256 139</PHONE_1><PHONE_2>+34 655 228 955</PHONE_2><FAX_1>+34 91 523 91 29</FAX_1></ADDRESS></PERSON><PERSON ID="6233" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Mario</FIRST_NAME><LAST_NAME>Fioravanti</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Clinical Psychology</POSITION><EMAIL_1>mario.fioravanti@uniroma1.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatric Science and Psychological Medicine</DEPARTMENT><ORGANISATION>University of Rome "La Sapienza"</ORGANISATION><ADDRESS_1>P.le A. Moro, 5</ADDRESS_1><CITY>Rome</CITY><ZIP>00185</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+3906 4991 ext: 2287</PHONE_1><PHONE_2>+3906 4451.622</PHONE_2><FAX_1>+3906 4451.622</FAX_1></ADDRESS></PERSON><PERSON ID="7556" ROLE="AUTHOR"><PREFIX>Sir</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Grimley Evans</LAST_NAME><POSITION>Professor Emeritus</POSITION><EMAIL_1>john.grimleyevans@green.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Clinical Geratology, Nuffield Department of Clinical Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Infirmary</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6HE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><FAX_1>+44 1865 224815</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-04-18 14:35:49 +0100" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="11" MONTH="4" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="3" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="7" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-14 09:43:45 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-14 09:43:45 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="23" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>An update search was performed on 23 March 2008. Possible new studies were identified for consideration by the authors.</P>
<P>The Lebert 2004 trial has been followed by an open-label extension study. 26 patients with frontotemporal dementia were followed for three years. The reported results showed that trazodone is well-tolerated and effective in dealing with FTD patients.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-04-04 10:47:08 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-04 10:47:08 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="15" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Update August 2006. Update searches were performed resulting in one new reference (the formal publication of Lebert 2004). This did not provide any new data for the analyses but was added to the Lebert 2004 included study reference. The Results and Conclusions of the review remain unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Dementia and Cognitive Improvement Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Division of Clinical Geratology, Nuffield Department of Clinical Medicine, University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-14 09:43:25 +0100" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-04-18 15:11:07 +0100" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-04-18 15:11:07 +0100" MODIFIED_BY="Helen Collins">Insufficient evidence from randomized, placebo-controlled studies to support a recommendation that trazodone should be prescribed, or not prescribed, for BPSD</TITLE>
<SUMMARY_BODY>
<P>The rationale for using trazodone is that it is a sedating atypical serotonergic antidepressant with a low rate of adverse effects and some behavioural and psychological symptoms in people with dementia (BPSD) are associated with serotonergic dysfunction. The conclusion is based on limited data from two small studies. The larger of the studies, conducted in 73 patients with Alzheimer's disease, showed no beneficial effect of trazodone at all. A smaller cross-over study in patients with frontal lobe dementia showed a trend for reduction in some symptoms in the first study period. Larger, longer studies are needed to explore the efficacy, effectiveness and safety of trazodone.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-04-18 14:38:31 +0100" MODIFIED_BY="Helen Collins">
<ABS_BACKGROUND>
<P>Behavioural and psychiatric disturbances affect at least 50% of people with Alzheimer's disease and other dementias. Neuroleptic drugs are extensively prescribed to treat behavioural manifestations of dementia in spite of only modest efficacy and a high frequency of adverse effects. There is clearly a need for safer and more effective remedies. Trazodone is a psychoactive compound with sedative and antidepressant properties, and with mixed serotonin agonist and antagonist effects. Functional serotonergic deficits may be related to the genesis of behavioural disturbances in dementia. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological cognition in people with dementia without an additional diagnosis of depression.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-04-11 11:11:42 +0100" MODIFIED_BY="[Empty name]">
<P>The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 23 March 2008 using the terms<B>: </B>trazodone* OR beneficat OR desirel OR sideril OR trazodil OR trazalon. The CDCIG Specialized Register contains records from all major health care databases (<I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All unconfounded, double-blind, randomised controlled trials, comparing trazodone with placebo in managing behavioural and psychiatric symptoms (except depression) in any type of dementia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Available data for this analysis were extracted from the two included studies and odds ratios or average differences, with 95% confidence intervals, calculated. Intention-to-treat analysis was undertaken where possible.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-04-18 14:38:31 +0100" MODIFIED_BY="Helen Collins">
<P>Two studies were included, comprising 104 participants with dementia. The trials differed in design: one a parallel-group study of patients with Alzheimer's disease and another a cross-over study of patients with frontotemporal dementia with an-open label follow-up trial of three years. The results from this extension study have not been used in the analysis. It was not possible to pool the data. The studies were respectively of 16 and six weeks duration, using trazodone from 50 to 300 mg daily. Both trials examined global clinical state, behavioural disturbances and cognitive function. The parallel study also assessed activities of daily living and caregiver burden. Compared with placebo, the use of trazodone was not associated with statistically significant benefits for behavioural manifestations as measured by various rating scales. Analysis of changes from baseline for clinical impression of change and for cognitive function did not produce statistically significant results in favour of trazodone. A variety of adverse effects were recorded with no significant differences between trazodone and placebo.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-04-11 11:05:33 +0100" MODIFIED_BY="[Empty name]">
<P>There is insufficient evidence to recommend the use of trazodone as a treatment for behavioural and psychological manifestations of dementia. In order to assess effectiveness and safety of trazodone, longer-term randomized controlled trials are needed, involving larger samples of participants with a wider variety of types and severities of dementia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-14 09:43:25 +0100" MODIFIED_BY="Helen Collins">
<BACKGROUND MODIFIED="2008-04-04 10:50:20 +0100" MODIFIED_BY="Helen Collins">
<CONDITION MODIFIED="2008-04-18 15:00:27 +0100" MODIFIED_BY="Helen Collins">
<P>Behavioural and psychiatric disturbances affect at least 50% of people with Alzheimer's disease and other dementias (<LINK REF="REF-Class-1997" TYPE="REFERENCE">Class 1997</LINK>). Agitation and other challenging manifestations are common, major problems in clinical management. The majority of people with dementia become agitated at some time during their illness, usually after two years from the onset of overt dementia, with a higher prevalence in nursing homes residents (<LINK REF="REF-Cohen_x002d_Mansfield-1989" TYPE="REFERENCE">Cohen-Mansfield 1989</LINK>). The International Psychogeriatric Association (IPA) Consensus Group classified heterogeneous non-cognitive manifestations of dementia into two categories (<LINK REF="REF-Finkel-2000" TYPE="REFERENCE">Finkel 2000</LINK>). The first category includes psychological manifestations including anxiety, depressive mood, hallucinations and delusions. The second category contains behavioural disturbances such as agitation, restlessness, wandering, physical aggression, inappropriate sexual activity, culturally inappropriate behaviours, hoarding, cursing, shadowing, screaming and sleep disorders.</P>
<P>Some non-psychotic features of dementia can be clustered under the non-specific term agitation, which usually denotes inappropriate motor, verbal or vocal activity (<LINK REF="REF-Cohen_x002d_Mansfield-1986" TYPE="REFERENCE">Cohen-Mansfield 1986</LINK>). Aberrant behaviours contribute a great deal to caregiver burden and can make home care for patients very difficult. They are generally associated with the need for institutionalisation, rapid cognitive decline, impaired quality of life and increased healthcare costs.</P>
<P>Environmental and social adjustments, other non-pharmacological interventions, and pharmacotherapy may become necessary for managing agitation (<LINK REF="REF-Devanand-1996" TYPE="REFERENCE">Devanand 1996</LINK>). Neuroleptic medication has been the mainstay of treatment of behavioural and psychological disturbances in elderly people. Neuroleptic drugs are extensively prescribed in spite of only modest efficacy and a high frequency of adverse effects (<LINK REF="REF-Schneider-1990" TYPE="REFERENCE">Schneider 1990</LINK>; <LINK REF="REF-Lanctot-1998" TYPE="REFERENCE">Lanctot 1998</LINK>; <LINK REF="REF-Ballard-1999" TYPE="REFERENCE">Ballard 1999</LINK>). However, elderly patients are particularly sensitive to the adverse antidopaminergic effects associated with all neuroleptics. Atypical neuroleptics were seen as a possible alternative to typical neuroleptics, offering similar effectiveness with fewer adverse effects (<LINK REF="REF-Schneider-1999" TYPE="REFERENCE">Schneider 1999</LINK>). In contrast with previous studies on conventional antipsychotics, randomised controlled trials of atypical neuroleptics include fairly large studies conducted to standards required by licensing authorities. However, use of atypical antipsychotics for the management of behavioural disturbances in older people has recently been proscribed in the United Kingdom and in other EC countries in the light of evidence of an enhanced risk of cerebrovascular disease (<LINK REF="REF-CSM-2004" TYPE="REFERENCE">CSM 2004</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-04-04 10:48:55 +0100" MODIFIED_BY="Helen Collins">
<P>The use of neuroleptics to treat behavioural features of dementia has been evaluated on several occasions. <LINK REF="REF-Schneider-1990" TYPE="REFERENCE">Schneider 1990</LINK> performed the first systematic review and meta-analysis of the existing corpus of controlled trials. The results indicated that around 18% of people with dementia benefited more from neuroleptic treatment than from placebo. These results were consistent with a modest efficacy of neuroleptics in agitated dementia. <LINK REF="REF-Lanctot-1998" TYPE="REFERENCE">Lanctot 1998</LINK> reviewed the English language literature published from 1966 to 1995. She investigated both efficacy and safety of the use of neuroleptics in comparison with placebo for behavioural disorders associated with dementia. She concluded that "neuroleptics have small but significant efficacy over placebo, and the efficacy rate is equivalent to the side effect rate". Until recently, typical neuroleptics appear to be the most widely used. Among these, haloperidol is most commonly prescribed for older people. However, according to the findings of a Cochrane review (<LINK REF="REF-Lonergan-2004" TYPE="REFERENCE">Lonergan 2004</LINK>), the evidence in support of the systematic use of haloperidol in agitated dementia is limited.</P>
<P>There is clearly a need for safer and more effective remedies (<LINK REF="REF-Ballard-1999" TYPE="REFERENCE">Ballard 1999</LINK>), and non-neuroleptic drugs, such as trazodone, carbamazepine, valproate, chloral hydrate, and serotonin re-uptake inhibitors, are increasingly used. There is little empirical evidence published on the effectiveness of these agents for treating challenging behaviours in elderly people with dementia. Although published evidence is inconclusive, physicians have been using trazodone, and following the Omnibus Budget Reconciliation Act 1987 (OBRA) its use has become common in United States nursing homes. OBRA's goal was to ensure the quality of care in nursing homes and to prevent misuse of antipsychotic medications (<LINK REF="REF-Shorr-1994" TYPE="REFERENCE">Shorr 1994</LINK>). By specifically defining indications for neuroleptics, OBRA effectively reduced their use (<LINK REF="REF-Elon-1992" TYPE="REFERENCE">Elon 1992</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2008-04-18 14:55:29 +0100" MODIFIED_BY="Helen Collins">
<P>Trazodone is a psychoactive compound with sedative and antidepressant properties. It was developed by the Italian Company, Angelini, during 1966 (<LINK REF="REF-Lehmann-1975" TYPE="REFERENCE">Lehmann 1975</LINK>) and is licensed in Europe and the United States for the treatment of depression. Trazodone is a phenyl-piperazine derivative of triazolopyridine, and is considered structurally different from other classes of antidepressant drugs, such as the tricyclics, tetracyclics and monoamine oxidase inhibitors. In contrast with other antidepressants, trazodone does not produce noticeable anticholinergic effects. Its mode of action is complex, particularly because it has mixed 5HT agonist and antagonist properties (<LINK REF="REF-Brogden-1981" TYPE="REFERENCE">Brogden 1981</LINK>). It is a post-synaptic 5HT antagonist, but has a 5HT agonist effect through its principal metabolite m-chlorophenylpiperazine (m-CPP) (<LINK REF="REF-Lawlor-1989" TYPE="REFERENCE">Lawlor 1989</LINK>), and is a weak global serotonin re-uptake inhibitor (<LINK REF="REF-Kahn-1991" TYPE="REFERENCE">Kahn 1991</LINK>).</P>
<P>Trazodone's main clinical effects are attributed to inhibition of serotonin re-uptake. Functional serotoninergic deficits may be related to the genesis of behavioural disturbances in people with dementia through the induction of depression and agitation (<LINK REF="REF-Mintzer-2001" TYPE="REFERENCE">Mintzer 2001</LINK>). In support of this hypothesis is the evidence that other serotoninergic agents, such as citalopram (<LINK REF="REF-Gottfries-1991" TYPE="REFERENCE">Gottfries 1991</LINK>) and buspirone (<LINK REF="REF-Sakauye-1993" TYPE="REFERENCE">Sakauye 1993</LINK>; <LINK REF="REF-Levy-1994" TYPE="REFERENCE">Levy 1994</LINK>) can be useful in treating agitation in dementia. A well-designed, placebo-controlled study of the serotonin re-uptake blocker citalopram (<LINK REF="REF-Gottfries-1991" TYPE="REFERENCE">Gottfries 1991</LINK>), showed significant improvement of emotional disturbance associated with Alzheimer's disease. There are some replicated studies (<LINK REF="REF-Cohen_x002d_Mansfield-1998" TYPE="REFERENCE">Cohen-Mansfield 1998</LINK>; <LINK REF="REF-McShane-1998" TYPE="REFERENCE">McShane 1998</LINK>) showing that people with early dementia who develop depression are more likely to display physical aggression later. This suggests that depression and aggression may result from the same pathophysiological process.</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-04-18 15:07:41 +0100" MODIFIED_BY="Helen Collins">
<P>Trazodone is widely regarded as a safe and effective treatment for depression among older people. Given its lack of anticholinergic effects and its good tolerability, trazodone has traditionally been used for the treatment of depression of older patients for whom the risks from reducing already lowered levels of cholinergic activity are high. Trazodone has been used in clinical trials as an active control treatment for older patients when a new compound was being tested (e.g. <LINK REF="REF-Passeri-1993a" TYPE="REFERENCE">Passeri 1993a</LINK>). There has, however, been little research on the efficacy of trazodone in controlling agitation; the limited data available are mainly case reports and clinical series (<LINK REF="REF-Nair-1973" TYPE="REFERENCE">Nair 1973</LINK>; <LINK REF="REF-Greenwald-1986" TYPE="REFERENCE">Greenwald 1986</LINK>; <LINK REF="REF-O_x0027_Neill-1986" TYPE="REFERENCE">O'Neill 1986</LINK>; <LINK REF="REF-Simpson-1986" TYPE="REFERENCE">Simpson 1986</LINK>; <LINK REF="REF-Tingle-1986" TYPE="REFERENCE">Tingle 1986</LINK>; <LINK REF="REF-Wilcock-1987" TYPE="REFERENCE">Wilcock 1987</LINK>; <LINK REF="REF-Pinner-1988" TYPE="REFERENCE">Pinner 1988</LINK>; <LINK REF="REF-Schneider-1989" TYPE="REFERENCE">Schneider 1989</LINK>; <LINK REF="REF-Lebert-1994" TYPE="REFERENCE">Lebert 1994</LINK>; <LINK REF="REF-Houlihan-1994" TYPE="REFERENCE">Houlihan 1994</LINK>; <LINK REF="REF-Galluzi-2000" TYPE="REFERENCE">Galluzi 2000</LINK>). Reviews (<LINK REF="REF-Schneider-1991" TYPE="REFERENCE">Schneider 1991</LINK>; <LINK REF="REF-Whitehouse-1995" TYPE="REFERENCE">Whitehouse 1995</LINK>; <LINK REF="REF-Yeager-1995" TYPE="REFERENCE">Yeager 1995</LINK>; <LINK REF="REF-Salzman-2001" TYPE="REFERENCE">Salzman 2001</LINK>) of the treatment of agitation in dementia mention the use of trazodone. <LINK REF="REF-Schneider-1991" TYPE="REFERENCE">Schneider 1991</LINK> reviewed the management of agitation in Alzheimer's disease and other dementias with non-neuroleptic medications. Trazodone, along with other drugs such as lithium, beta adrenergic blockers, carbamazepine, buspirone, l-deprenyl and serotonin uptake blockers were considered. Most of the trials had involved patients with various other organic mental syndromes but not affected specifically by dementia. The review concluded that there was little evidence for the efficacy of trazodone in the treatment of agitation in dementia or in Alzheimer's disease specifically. Later reviews (<LINK REF="REF-Whitehouse-1995" TYPE="REFERENCE">Whitehouse 1995</LINK>; <LINK REF="REF-Yeager-1995" TYPE="REFERENCE">Yeager 1995</LINK>; <LINK REF="REF-Salzman-2001" TYPE="REFERENCE">Salzman 2001</LINK>) also drew attention to a lack of firm evidence at that time of the efficacy of trazodone despite the encouraging clinical experience reported in the literature.</P>
<P>The aim of this review is to assess the efficacy of trazodone in the management of behavioural and psychotic manifestations in people with dementia. We will exclude the additional diagnosis of depression because 'depression and dementia' are addressed in a separate review (<LINK REF="REF-Bains-2004" TYPE="REFERENCE">Bains 2004</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological manifestation, for people with dementia without an additional diagnosis of depression.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All unconfounded, double-blind, randomised trials investigating the effectiveness of trazodone for behavioural and psychotic manifestations in any type of dementia.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-05-14 09:41:31 +0100" MODIFIED_BY="Helen Collins">
<UL>
<LI>Any age and either sex</LI>
<LI>Setting: inpatients and outpatients</LI>
<LI>Diagnosed with dementia of any type and severity, or cognitive impairment according to internationally accepted criteria such as NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) (<LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>), DSM-IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>) and ICD. Other evidence such as Mini-Mental State Examination (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>), Clinical Dementia Rate (<LINK REF="REF-Hughes-1982" TYPE="REFERENCE">Hughes 1982</LINK>), Global Deterioration Scale (<LINK REF="REF-Reisberg-1982" TYPE="REFERENCE">Reisberg 1982</LINK>) and other medical, psychiatric or psychological evaluation will be accepted in the absence of these criteria, to assess cognitive function</LI>
<LI>Previous history of behavioural disturbances as measured by the rating scales used in the selected studies</LI>
<LI>At least one week free of psychotropic medications prior to commencing the study.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trazodone given at any dose and for any time period compared with placebo.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Outcomes of interest will include:<BR/>
</P>
<UL>
<LI>effect on behavioural and psychological manifestations as measured by the rating scales used in the selected studies</LI>
<LI>clinical Global Impression of Change </LI>
<LI>safety and acceptability of treatment as measured by the incidence of adverse effects and withdrawal rates.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-14 09:43:25 +0100" MODIFIED_BY="Helen Collins">
<P>See <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html">Cochrane Dementia and Cognitive Improvement Group</A> methods used in reviews.</P>
<P>The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG) was searched on 23 March 2008 for all years up to December 2005. This register contains records from the following major healthcare databases <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS, and many ongoing trial databases and other grey literature sources. The following search terms were used: trazodon* OR beneficat OR desirel OR sideril OR trazodil OR trazalon</P>
<P>
<I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched separately on 23 March 2008 for records added to these databases after December 2005 to January 2008. The search terms used to identify relevant controlled trials on dementia, Alzheimer's disease and mild cognitive impairment for the Group's Specialized Register can be found in the Group's module on <I>The Cochrane Library</I>. These search terms were combined with the following search terms and adapted for each database, where appropriate: trazodon* OR beneficat OR desirel OR sideril OR trazodil OR trazalon.</P>
<P>On 23 March 2008, the Specialized Register consisted of records from the following databases:</P>
<P>
<B>Healthcare databases:</B>
</P>
<UL>
<LI>
<I>The Cochrane Library</I> (2006, Issue 1);</LI>
<LI>MEDLINE (1966 to 2006/07, week 5);</LI>
<LI>EMBASE (1980 to 2006/07);</LI>
<LI>PsycINFO (1887 to 2006/08, week 1);</LI>
<LI>CINAHL (1982 to 2006/06);</LI>
<LI>SIGLE (Grey Literature in Europe) (1980 to 2005/03);</LI>
<LI>LILACS: Latin American and Caribbean Health Science Literature (http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F) (last searched 29 August 2006).</LI>
</UL>
<P>
<B>Conference proceedings:</B>
</P>
<UL>
<LI>ISTP (http://portal.isiknowledge.com/portal.cgi) (Index to Scientific and Technical Proceedings) (to 29 August 2006);</LI>
<LI>INSIDE (BL database of Conference Proceedings and Journals) (to June 2000);.</LI>
</UL>
<P>
<B>Theses:</B>
</P>
<UL>
<LI>Index to Theses (formerly ASLIB) (http://www.theses.com/) (UK and Ireland theses) (1716 to 11 August 2006);</LI>
<LI>Australian Digital Theses Program (http://adt.caul.edu.au/): (last update 24 March 2006);</LI>
<LI>Canadian Theses and Dissertations (http://www.collectionscanada.ca/thesescanada/index-e.html): 1989 to 28 August 2006);</LI>
<LI>DATAD - Database of African Theses and Dissertations (http://www.aau.org/datad/backgrd.htm);</LI>
<LI>Dissertation Abstract Online (USA) (http://wwwlib.umi.com/dissertations/gateway) (1861 to 28 August 2006).</LI>
</UL>
<P>
<B>Ongoing trials:</B>
</P>
<P>
<I>UK</I>
</P>
<UL>
<LI>National Research Register (http://www.update-software.com/projects/nrr/) (last searched issue 3/2006);</LI>
<LI>ReFeR (http://www.refer.nhs.uk/ViewWebPage.asp?Page=Home) (last searched 30 August 2006);</LI>
<LI>Current Controlled trials: Meta Register of Controlled trials (mRCT) (http://www.controlled-trials.com/) (last searched 30 August 2006) </LI>
<LI>ISRCTN Register - trials registered with a unique identifier</LI>
<LI>Action medical research</LI>
<LI>Kings College London</LI>
<LI>Laxdale Ltd</LI>
<LI>Medical Research Council (UK)</LI>
<LI>NHS Trusts Clinical Trials Register</LI>
<LI>National Health Service Research and Development Health Technology Assessment Programme (HTA)</LI>
<LI>National Health Service Research and Development Programme 'Time-Limited' National Programmes</LI>
<LI>National Health Service Research and Development Regional Programmes</LI>
<LI>The Wellcome Trust</LI>
<LI>Stroke Trials Registry (http://www.strokecenter.org/trials/index.aspx) (last searched 31 August 2006);</LI>
</UL>
<P>
<I>Netherlands</I>
</P>
<P>Nederlands Trial Register (http://www.trialregister.nl/trialreg/index.asp) (last searched 31 August 2006);</P>
<P>
<I>USA/International</I>
</P>
<UL>
<LI>ClinicalTrials.gov (http://www.ClinicalTrials.gov) (last searched 31 August 2006) (contains all records from http://clinicalstudies.info.nih.gov/);</LI>
<LI>IPFMA Clinical trials Register: www.ifpma.org/clinicaltrials.html. The Ongoing Trials database within this Register searches http://www.controlled-trials.com/isrctn, http://www.ClinicalTrials.gov and http://www.centerwatch.com/. The ISRCTN register and Clinicaltrials.gov are searched separately. Centerwatch is very difficult to search for our purposes and no update searches have been done since 2003.</LI>
<LI>The IFPMA Trial Results databases searches a wide variety of sources among which are:</LI>
<LI>http://www.astrazenecaclinicaltrials.com (seroquel, statins)</LI>
<LI>http://www.centerwatch.com</LI>
<LI>http://www.clinicalstudyresults.org</LI>
<LI>http://clinicaltrials.gov</LI>
<LI>http://www.controlled-trials.com</LI>
<LI>http://ctr.gsk.co.uk</LI>
<LI>http://www.lillytrials.com (zyprexa)</LI>
<LI>http://www.roche-trials.com (anti-abeta antibody)</LI>
<LI>http://www.organon.com</LI>
<LI>http://www.novartisclinicaltrials.com (rivastigmine)</LI>
<LI>http://www.bayerhealthcare.com</LI>
<LI>http://trials.boehringer-ingelheim.com</LI>
<LI>http://www.cmrinteract.com</LI>
<LI>http://www.esteve.es</LI>
<LI>http://www.clinicaltrials.jp</LI>
</UL>
<P>
<I>This part of the IPFMA database is searched and was last updated on 4 September 2006;</I>
</P>
<UL>
<LI>Lundbeck Clinical Trial Registry (http://www.lundbecktrials.com) (last searched 15 August 2006);</LI>
<LI>Forest Clinical trial Registry (http://www.forestclinicaltrials.com/) (last searched 15 August 2006).</LI>
</UL>
<P>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS can be found in the Group's module on <I>The Cochrane Library.</I>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-04-18 14:41:49 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Irrelevant citations were discarded by a review of the title of the publication and its abstract. In the presence of any suggestion that the article could possibly be relevant, it was retrieved for further assessment. The reviewers selected the trials for inclusion in the review from the culled citation list.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>One reviewer (GMT) assessed the methodological quality of each trial with particular emphasis on the allocation concealment, which was ranked using the Cochrane approach:<BR/>
</P>
<UL>
<LI>Category A (adequate concealment) is where the report describes allocation of treatment by: (i) some form of centralized randomised scheme, such as having to provide details of an enrolled participant to an office by phone to receive the treatment group allocation; (ii) some form of randomisation scheme controlled by a pharmacy; (iii) numbered or coded containers, such as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are administered sequentially to enrolled participants; (iv) an on-site or coded computer system, given that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participant; or (v) if assignment envelopes were used, the report should at least specify that they were sequentially numbered, sealed, opaque envelopes; (vi) other combinations of described elements of the process that provides assurance of adequate concealment.</LI>
<LI>Category B (unclear) is where the report describes allocation of treatment by: (i) use of a list or table to allocate assignments; (ii) use of envelopes or sealed envelopes; (iii) statement that the study was randomised without further detail.</LI>
<LI>Category C (inadequate) is where the report describes allocation of treatment by: (i) alternation; (ii) reference to case record numbers, dates of birth, day of week, or any such approach; (iii) any allocation procedure that is entirely transparent before assignment, such as an open list of random numbers or assignments; no explicit assurance of randomisation.</LI>
</UL>
<P>Empirical research has shown that lack of adequate allocation concealment is associated with bias. Trials with unclear concealment measures have been shown to yield more pronounced estimates of treatment effects than trials that have taken adequate measures to conceal allocation schedules, but less pronounced than inadequately concealed trials (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Trials were included if they conformed to categories A or B, while those falling into category C were excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Data were extracted from the published reports. The summary statistics required for each trial and each outcome for continuous data were the mean change from baseline, the standard error of the mean change, and the number of patients for each treatment group at each assessment. Where changes from baseline were not reported, the mean, standard deviation and the number of patients for each treatment group at each time point were extracted if available. For binary data the numbers in each treatment group and the numbers experiencing the outcome of interest were sought.</P>
<P>The baseline assessment is defined as the latest available assessment prior to randomisation, but no longer than two months before.</P>
<P>For each outcome measure, data were sought on every patient assessed. To allow an intention-to-treat analysis (ITT), the data were sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If ITT data were not available, an analysis of patients who completed treatment was conducted. The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the trials had a reasonably large number of ordered categories (more than 10) the data were treated as continuous outcomes arising from a normal distribution.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>Summary statistics (n, mean and standard deviation) are required for each rating scale at each assessment time for each treatment group in each trial for change from baseline.</P>
<P>When change from baseline results were not reported, the required summary statistics were calculated from the baseline and assessment time treatment group means and standard deviations. In this case a zero correlation between the measurements at baseline and assessment time is assumed. This method overestimates the standard deviation of the change from baseline, but this conservative approach is considered to be preferable in a meta-analysis.</P>
<P>The measure of the treatment difference for any outcome is the weighted mean difference when the pooled trials use the same rating scale or test. For binary outcomes, such as clinical improvement or no clinical improvement, the odds ratio is used to measure treatment effect.</P>
<P>For continuous or ordinal variables, such as psychometric test scores, clinical global impression scales, functional and quality of life scales, there are two possible approaches. If ordinal scale data appear to be approximately normally distributed, or if the analysis that the investigators performed suggests parametric tests are appropriate, then the outcome measures are treated as continuous data. The second approach, which may not exclude the first, is to concentrate into 2 categories that best represent the contrasting states of interest, and to treat the variable as binary.</P>
<P>A weighted estimate of the typical treatment effect across trials is calculated. Overall estimates of the treatment difference are presented. In all cases the overall estimate from a fixed effects model is presented and a test for heterogeneity using I2 statistic performed. Where there is evidence of heterogeneity of the treatment effect between trials then either only homogeneous results are pooled, or a random-effects model is used (in which case the confidence intervals would be broader than those of a fixed-effects model).<BR/>
<BR/>Subgroup analyses may be carried out for different types of dementia.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-04-18 15:00:40 +0100" MODIFIED_BY="Helen Collins">
<P>Two studies were identified that met the inclusion criteria (<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>; <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>). The characteristics are summarized in the table of included studies, and an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, Baseline characteristics of the included trials) describes details of the diagnostic criteria and baseline characteristics of participants, country, study design, trial size, intervention and duration.</P>
<SUBSECTION>
<HEADING LEVEL="3">Methods</HEADING>
<P>Both trials were multicentre, double-blind and randomised studies comparing trazodone with placebo. A parallel design was used in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> with a 16-week total duration. In eleven of the twelve sites, subjects were randomly allocated to four study arms - trazodone, haloperidol, behavioural management techniques (BMT) and placebo. In the 12th site, randomisation excluded the BMT arm. <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> employed a cross-over design, with two 6-week periods, where participants were randomly assigned to a sequence of placebo-trazodone or trazodone-placebo, without a washout period separating the phases.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>The numbers of participants randomised to trazodone or placebo in the studies were 73 (<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>) and 31 (<LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>). Both studies were of patients living at home. The trials varied in terms of their inclusion and exclusion criteria. In <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>, the diagnosis of probable or possible Alzheimer's Disease was made according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA) (<LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>). <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> enrolled people with frontotemporal dementia (FTD) diagnosed according to the Lund and Manchester group criteria (<LINK REF="REF-Lund-Manchester-1994" TYPE="REFERENCE">Lund Manchester 1994</LINK>). Participants were required to have had a previous history of behavioural disturbances assessed by various scales such as ABID (<LINK REF="REF-Logsdon-1999" TYPE="REFERENCE">Logsdon 1999</LINK>), CERAD-BRSD (<LINK REF="REF-Tariot-1995" TYPE="REFERENCE">Tariot 1995</LINK>), CMAI (<LINK REF="REF-Cohen_x002d_Mansfield-1996" TYPE="REFERENCE">Cohen-Mansfield 1996</LINK>, <LINK REF="REF-Koss-1997" TYPE="REFERENCE">Koss 1997</LINK>) and NPI (<LINK REF="REF-Cummings-1994" TYPE="REFERENCE">Cummings 1994</LINK>). A history of at least 2 weeks of two or more agitated behaviours occurring at least once weekly was specified in the inclusion criteria for <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>.</P>
<P>The criteria excluded patients with major psychiatric disorders (such as depression), neurological or systemic illness (e.g. delirium, hypoxia or unstable thyroid dysfunction are specified in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>). Evidence of addiction (alcohol or drug abuse), or need for emergency treatment for agitation was another exclusion reason. Concomitant use of psychotropic agents was not allowed during study enrolment, and use of these medications was required to have ceased at least 2 weeks before enrolment in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>, and 4 weeks before in <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>.</P>
<P>Mean ages were 75.2 (<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>) and 61.7 (<LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>). Of the 31 participants in <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>, 16 were women, and in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> 53% were women. In addition to age and sex, <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> detailed education, ethnic group, relationship between patient and caregiver, onset and duration of dementia. The mean MMSE in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> was 13-14 and in <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> was 21.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Both trials were designed to compare trazodone with placebo. Both studies started with low doses progressively increased in response to observed adverse effects. Dosage at the end of the observation period was either 150mg or 300mg/d in <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>, and was a mean of 200mg/d in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>.</P>
<P>
<LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> had two 6 weeks periods. During the trazodone phase, the initial dose was 50mg then 100mg in an initial six days titration. Then the participants received 150mg/d for 3 weeks. Then, if they did not suffer adverse effects, 300mg/d of trazodone was prescribed to complete the 6-week period.</P>
<P>In <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> participants began with one 50mg tablet each day. At subsequent clinic visits dosage was increased by 50mg a day, until improvement of agitation or adverse effects appeared, or maximum dose of 300mg per day was attained. The participants in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> were examined at follow-up 12 months after the 4 month randomised study to determine if behaviour management techniques (BMTs) reduced long-term psychotropic use (<LINK REF="REF-Weiner-2002" TYPE="REFERENCE">Weiner 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>The primary outcome in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> was the Clinical Global Impression of Change (ADCS-CGIC) (<LINK REF="REF-Schneider-1997" TYPE="REFERENCE">Schneider 1997</LINK>). The severity of the behavioural disturbances assessed by the Neuropsychiatric Inventory (NPI) (<LINK REF="REF-Cummings-1994" TYPE="REFERENCE">Cummings 1994</LINK>) was the primary measure in <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>. Many different rating scales and test were used to assess other secondary outcomes in the trials. Besides changes from baseline behavioural disturbances, caregiver burden and functional disturbances were also measured in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>. Details of the outcomes and all the scales are summarized in additional tables (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) and described below:</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Global assessment</HEADING>
<P>The Clinical Global Impression of Change (CGIC) (<LINK REF="REF-Schneider-1997" TYPE="REFERENCE">Schneider 1997</LINK>) is a seven-point scale evaluating the amount of change in overall impairment from the study baseline. Score 1 indicates extreme improvement, 4 no change and 7 extreme worsening. The same clinician is required to assess a participant at baseline and follow-up. No structured interview is used and the rating is based on caregiver interview and examination of the participant. To facilitate clinical interpretation, <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> collapsed the seven categories of the Alzheimer Disease Cooperative Study Clinical Global Impression of Change (ADCS-CIGC) into "improved", "no change" and "worse". It was assumed that participants who dropped out did so because they had become worse. A rating of "worse" was applied, and then confirmed by a review of caregivers' reasons for the withdrawal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Behavioural measures</HEADING>
<P>1. The Agitated Behavior Inventory for Dementia (ABID) (<LINK REF="REF-Logsdon-1999" TYPE="REFERENCE">Logsdon 1999</LINK>) is a 16-item instrument applied by caregivers of people with dementia. Caregivers rate behaviours first according to frequency of occurrence and then to the intensity of their own reaction to each problem behaviour. The frequency score ranging from 0 (did not occur) to 3 (occur daily or more often), and reaction score from 0 (not upsetting) to 4 (extreme upsetting).</P>
<P>2. The Consortium to Establish a Registry of Alzheimer's Disease Behavioral Rating Scale for Dementia (CERAD-BRSD) (<LINK REF="REF-Tariot-1995" TYPE="REFERENCE">Tariot 1995</LINK>) assesses behavioural disturbances in patients with Alzheimer's disease. It covers domains of depression, psychotic features, irritability and agitation, vegetative features, apathy, aggression and affective lability. The items are rated on an 4-point scale to measure frequency. A high score indicates severe impairment.</P>
<P>3. The Cohen-Mansfield Agitation Inventory (CMAI) (<LINK REF="REF-Cohen_x002d_Mansfield-1996" TYPE="REFERENCE">Cohen-Mansfield 1996</LINK>; <LINK REF="REF-Koss-1997" TYPE="REFERENCE">Koss 1997</LINK>) assesses the frequency of 36 agitated behaviours rated on a seven point scale (1: never occurs to 7: occurs several times an hour). It examines aggressive behaviour, physically non-aggressive behaviour and verbally agitated behaviour.</P>
<P>4. Neuropsychiatric Inventory (NPI) (<LINK REF="REF-Cummings-1994" TYPE="REFERENCE">Cummings 1994</LINK>) is a 12-item instrument evaluating the frequency and severity of behavioural and neuropsychiatric disturbances (hallucinations, delusions, anxiety, agitation/aggression, depression/dysphoria, elation/euphoria, irritability, disinhibition, aberrant motor behaviour, night-time behaviour and eating disorders). The scores range from 0 to 144, with lower score indicating milder disturbances. In <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> it was decided that patients with a NPI score reduction of 50% or more should be classified as responders in view of the severity of behavioural disturbances and the poor response to treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cognitive function</HEADING>
<P>The Mini-Mental State Examination (MMSE) (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>) was developed as a short test for screening for dementia among older people but has become widely used as an assessment instrument. It concentrates on the cognitive aspects of mental function. The five sections cover orientation, immediate recall, attention and calculation, delayed recall and language. The maximum score of 30 indicates absence of impairment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Activities of daily living</HEADING>
<P>
<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> used the Physical Self Maintenance (PSM) and Instrumental Activities of Daily Living (IADL) scales (<LINK REF="REF-Lawton-1969" TYPE="REFERENCE">Lawton 1969</LINK>) to measure functional disturbances. The scale assesses physical self-maintenance and the ability to perform complex daily tasks: ability to use the telephone, transportation, shopping, food preparation, household tasks, laundry, responsibility for own medications and ability to manage finances.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Caregiver burden</HEADING>
<P>1.The Screen for Caregiver Burden (SCB) (<LINK REF="REF-Vitaliano-1991" TYPE="REFERENCE">Vitaliano 1991</LINK>) is a 25-item checklist assessing two aspects of caregiver burden - objective burden (number of items checked) and subjective burden (degree of distress).</P>
<P>2. With the Revised Memory and Behavior Problem Checklist (RMBPC) (<LINK REF="REF-Teri-1992" TYPE="REFERENCE">Teri 1992</LINK>), caregivers rate 24 problems on two 5-point scales: frequency of problems and caregiver distress from each problem. A global score and three sub scale scores are obtained for each scale (memory-related, depressive and disruptive).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety and tolerability </HEADING>
<P>Safety and tolerability were evaluated by recording adverse events. <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> measured the frequency of adverse events using a checklist; safety was reviewed by a Safety Monitoring Committee. The 11 adverse events monitored were: drooling, parkinsonian gait, dry mouth, dizziness, akathisia, rigidity, dyskinesia, drowsiness, bradykinesia, tremor and fatigue. Other adverse effects such as hypotension or cold extremities were assessed in <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> by open-ended questioning of participants and their carers.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Two randomised, double-blind studies were eligible for inclusion in the review, one parallel-group (<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>) and the other one cross-over in design (<LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>). Neither trial described the method of randomisation and were therefore classified in Category B criteria for allocation concealment. Placebo and treatment groups did not differ in baseline characteristics. All participants or their legal representatives signed an informed consent form before entering the study. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-14 09:39:44 +0100" MODIFIED_BY="Helen Collins">
<P>
<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> used a parallel-group design to compare the effects of trazodone with those of placebo after 16 weeks of treatment. <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> reports a cross-over study of two 6-week periods, with no washout period between the two treatment phases. Only data from the first phase are included in this analysis. The two studies also differed in the duration of treatment, type of dementia and scales used to assess the different outcomes. They only concurred in the Global Assessment and in the use of the MMSE to assess cognitive function. Only one statistical significant difference (defined as P &lt; 0.05) emerged in analysis. A benefit favouring placebo was seen in MMSE scores in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>. Both studies reported statistical analyses based on intention-to-treat (ITT). Few usable data could be extracted from the two studies. The different designs of the trials prevented pooling of data so results are presented separately.</P>
<P>
<B>Effects of trazodone ( mean dose 200 ± 75 mg/day) in patients with Alzheimer's disease, for 16 weeks (parallel design) - </B>
<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>
<B>
<BR/>
</B>
</P>
<UL>
<LI>
<I>Global Assessment</I>
</LI>
</UL>
<P>The CGI scale, measuring clinical global impression of change, was categorized into improved, unchanged or worse. A value of "worse" was assigned if no ADCS-CGIC score was available. Participants who dropped out were assumed to have become worse. This was confirmed at the end of the study by the reasons given by caregivers for the dropping out. Eight per cent of a total of 148 participants were affected, but we cannot determine which of them specifically belonged to the trazodone group. The result of this primary outcome, showed that of all participants, 34% improved relative to baseline, and there were no significant differences between treatment and placebo groups:<BR/>CGIC-improvement (15/37 compared with 11/36, OR 1.55, 95% CI 0.59 to 4.07, P = 0.37)<BR/>CGIC-no change (5/37 compared with 10/36, OR 0.41, 95% CI 0.12 TO 1.34, P = 0.14)<BR/>CGIC-worse (17/37 compared with 15/36, OR 1.19, 95% CI 0.47 to 3.00, P = 0.71)</P>
<UL>
<LI>
<I>Behavioral disturbances</I>
</LI>
</UL>
<P>Several rating scales were used to assess behavioral disturbances (ABID, CERAD-BRSD, CMAI). For all measures a positive change indicates increased impairment. There were no statistically significant differences between treatment (trazodone mean dose 200 mg daily) and placebo groups in change from baseline at 16 weeks:<BR/>1.ABID -frequency ( WMD -1.95, 95% CI -9.52 to 5.62, P = 0.61)<BR/>ABID-reaction ( WMD -0.28, 95% CI -5.44 to 4.88, P = 0.92)<BR/>ABID-total (WMD -0.81, 95% CI -5.07 to 3.45, P = 0.72)<BR/>2.CERAD-BRSD (WMD -1.67, 95% CI -12.09 to 8.75, P = 0.75)<BR/>3.CMAI (WMD 5.18, 95% CI -2.86 to 13.22, P = 0.21)</P>
<UL>
<LI>
<I>Function</I>
</LI>
</UL>
<P>Measures of Physical Self Maintenance (PSM) and Instrumental Activities of Daily Living (IADL) did showed no statistically significant differences between trazodone and placebo:<BR/>PMS (WMD 0.31, 95% CI -0.84 to 1.46, P = 0.60)<BR/>IADL (WMD 0.92, 95% CI-0.60 to 2.44, P = 0.24)</P>
<UL>
<LI>
<I>Caregiver burden</I>
</LI>
</UL>
<P>There were not statistically significant differences between trazodone and placebo in either of the two scales used:<BR/>1. SCB-objective (WMD 0.11, 95% CI -1.74 to 1.96, P = 0.91)<BR/>SCB-subjective (WMD 0.61, 95% CI -3.92 to 5.14, P = 0.79)<BR/>2. RMBPC (MWD -0.11, 95% CI -0.38 to 0.16, P = 0.43)</P>
<UL>
<LI>
<I>Cognitive function</I>
</LI>
</UL>
<P>The trial revealed statistically significant worsening of cognitive function, as measured by change from baseline in MMSE score, for trazodone compared with placebo at 16 weeks.<BR/>MMSE (MWD -1.69, 95% CI -3.18 to -0.20, P = 0.03)</P>
<UL>
<LI>
<I>Adverse effects</I>
</LI>
</UL>
<P>Eleven different types of adverse events were reported. Analysis of individual adverse symptoms stated no significant differences between trazodone and placebo groups:<BR/>1.Drooling ( 0/37 trazodone compared with 0/36 placebo, OR not estimable)<BR/>2.Parkinson gait (4/37 compared with 3/36, OR 1.33, 95% CI 0.28 to 6.43, P = 0.72)<BR/>3.Dry mouth (7/37 compared with 5/36, OR 1.45, 95% CI 0.41 to 5.06, P = 0.56)<BR/>4.Dizziness (7/37 compared with 3/36, OR 2.57, 95% CI 0.61 to 10.83, P = 0.20)<BR/>5.Akathesia (1/37 compared with 4/36, OR 0.22, 95% CI 0.02 to 2.09, P = 0.19)<BR/>6.Rigidity (3/37 compared with 5/36, OR 0.55, 95% CI 0.12 to 2.48, P = 0.43)<BR/>7.Dyskinesia (0/37 compared with 5/36, OR 0.08, 95% CI 0.00 to 1.44, P = 0.09)<BR/>8.Drowsiness (7/37 compared with 5/36, OR 1.45, 95% CI 0.41 to 5.06, P = 0.56)<BR/>9.Bradykinesia (7/37 compared with 7/36, OR 0.97, 95% CI 0.30 to 3.10, P = 0.95)<BR/>10.Tremor (4/37 compared with 5/36, OR 0.75, 95% CI 0.18 to 3.06, P = 0.69)<BR/>11. Fatigue (4/37 compared with 6/36, OR 0.61, 95% CI 0.16 to 2.36, P = 0.47)</P>
<UL>
<LI>
<I>Drops-outs by endpoint</I>
</LI>
</UL>
<P>The main reason for dropping out was agitation (50%). There was no evidence of any difference between trazodone and placebo groups:<BR/>12/37 compared with 11/36, OR 1.09, 95% CI 0.41 to 2.93, P = 0.86<BR/>
<B>
<BR/>Effects of Trazodone (range dose 50 to 300 mg per day) in patients with frontotemporal dementia, for six weeks (cross-over design): </B>
<LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>
<BR/>
</P>
<UL>
<LI>
<I>Behavioral disturbances </I>
</LI>
</UL>
<P>The primary outcome measure was the Neuropsychiatric Inventory (NPI). Owing to the known severity and lack of response to treatment of behavioral disturbances, participants with a NPI score reduction of 50% or more were categorized as responders. Over the full two periods of the cross-over trial, the NPI total scores suggested statistically significant benefit from trazodone compared with placebo. However, restricting analysis to data from the first 6-week period, there were no statistically significant differences between treatment and placebo groups (WMD -0.80, 95% CI -13.35 to 11.75, P = 0.90)</P>
<UL>
<LI>
<I>Global assessment</I>
</LI>
</UL>
<P>There were no statistically significant differences between treatment and placebo groups in Global Change Impression Improvement: (WMD 0.50, 95% CI -1.38 to 0.38, P = 0.27)</P>
<UL>
<LI>
<I>Cognitive function</I>
</LI>
</UL>
<P>There were no statistically significant differences between treatment and placebo groups in MMSE scores: (WMD -0.10, 95% CI -5.98 to 5.78, P = 0.97)</P>
<UL>
<LI>
<I>Side effects </I>
</LI>
</UL>
<P>There were no statistically significant differences between treatment and placebo groups in the numbers of patients suffering adverse effects:<BR/>1. Fatigue (1/15 trazodone compared with 2/16 placebo, OR 0.50, 95% CI 0.04 to 6.17, P = 0.59)<BR/>2. Dizziness (1/15 trazodone compared with 0/16 placebo, OR 3.41, 95% CI 0.13 to 90.49, P = 0.46)<BR/>3. Cold extremities (0/15 trazodone compared with 1/16 placebo, OR 0.33, 95% CI 0.01 to 8.33, P = 0.51)</P>
<UL>
<LI>
<I>Drop-outs</I>
</LI>
</UL>
<P>During the first treatment period of this cross-over trial, three participants taking trazodone dropped out for various reasons (hypotension, agitation, non-elective surgery). There were no differences between treatment and placebo groups in the frequency of these events:<BR/>1. Adverse event (1/15 compared with 0/16, OR 3.41 95% CI 0.13 to 90.49, P = 0.46)<BR/>2. Lack of efficacy (1/15 compared with 0/16, OR 3.41 95% CI 0.13 to 90.49, P = 0.46)<BR/>3. Non-elective surgery (1/15 compared to 0/16, OR 3.41 95% CI 0.13 to 90.49, P = 0.46)</P>
<SUBSECTION>
<HEADING LEVEL="3">2008 update</HEADING>
<P>No further studies were identified in the new search for inclusion in the review. One long-term open-label trial was retrieved in the new search. This was an extension to a 12-week randomized, double-blind, placebo-controlled cross-over study design (<LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>). 26 patients with frontotemporal FTD diagnosis were entered and followed up for three years. 14 women and 12 men with average age 60 (± 9.3) years, mean Mini-Mental State Examination (MMSE) =20.7(± 8.6) and neuropsychiatry inventory score (NPI) = 53.3 (±18.7). Patients received 300 mg/day trazodone for 112 weeks after the end of the randomization period. All the safety and efficacy measures were assessed twice a year. Both physical examination and scoring on the MMSE were applied to assess safety at each visit. The results of this study cannot be used in a meta-analysis in this review owing to the open-label design.</P>
<P>The following results were reported in the trial:</P>
<P>
<I>Drop-out rate</I>: The withdrawal rate was 23% (n = 6) in the first year. Two died, two were institutionalized and two refused the follow-up. In the second year the drop-out rate was 15% (n = 4) due to increase of dementia and decrease in the behavioural disturbance. None of the patients dropped out as a result of a drug side-effects.</P>
<P>
<I>Adverse event</I>s: Hypotension was the single side effect occurring at this long term follow-up in four patients.</P>
<P>
<I>Behavioural disturbances:</I> In<I> </I>16 patients who had been treated with trazodone for over two years. No patients had an increase in the neuropsychiatry inventory (NPI) score compared to baseline measures. The mean difference in the final NPI score compared to baseline was 20.5 points ± 9.5.</P>
<P>
<I>Cognitive function:</I> Nine out of 16 patients had a decrease in MMSE of more than three points in comparison with baseline score, and seven had no changes or minor decrease of MMSE. The mean difference in MMSE at final point compared to baseline was 13.2 (± 12.9).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-04-18 14:50:47 +0100" MODIFIED_BY="Helen Collins">
<P>Given the relationship between serotonin dysfunction and behavioral disturbances, it was reasonable to expect that the trazodone's serotonergic effect might have a role in the treatment of behavioral disturbances in dementia. However, there is no evidence to support this hope. The present study cannot conclude that trazodone is ineffective, nor that it should not be prescribed, but there are no data to support its use in managing behavioral disturbances in dementia.</P>
<P>The main problem faced by this review is the limited number of eligible studies. Only two randomised trials (<LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK>; <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK>) met the inclusion criteria, and their different designs prevented pooling of their data. The studies also differed in numbers of participants, the inclusion and exclusion criteria applied, the types of dementia studied, the duration of treatment, and except for MMSE and Global Assessments, the rating scales by which outcomes were assessed. Dosages were similar in the two studies, from 50 to 300 mg daily, and without substantial adverse effects. The small sample employed in the trials gave them little power to detect effects of statistically significant magnitude. Interperetation of the results from the <LINK REF="STD-Lebert-2004" TYPE="STUDY">Lebert 2004</LINK> long-term open-label trial is limited, owing to the small number of the patients that were enrolled in the trial and the lack of a control group. </P>
<P>The patients enrolled in the trials were classified according to different criteria, since they suffered from different forms of dementia. The studies were similar in that the severity of dementia was defined by MMSE score. However, we should be aware that the participants in these studies may not be fully representative of the cognitively impaired older people in the community since there are several different causes of dementia and it is not always easy to characterize them unequivocally.</P>
<P>The results provided no evidence that trazodone is any more effective than placebo in treating agitation in older people with dementia.The finding in <LINK REF="STD-Teri-2000" TYPE="STUDY">Teri 2000</LINK> suggesting that trazodone may cause impairment of cognitive function needs to be borne in mind in the design of future studies but, in the context of multiple comparisons may merely reflect the play of chance. The trials were small and of low statistical power. Trazodone was well tolerated and in view of the theoretical rationale for a possible role for serotonergic agents in treating agitation in people with dementia further larger and longer-term trials are to be desired. However, agitation in people with dementia is probably heterogeneous in pathogenesis and serotonin-related mechanisms relevant in only a proportion. This has implications both for the size of studies and for their design in terms of ability to identify possible trazodone-responsive or -resistant subgroups.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is insufficient evidence from randomised, placebo-controlled studies to support a recommendation that trazodone should be prescribed, or not prescribed, for behavioral and psychological symptoms in people with dementia (BPSD).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Given the theoretical rationale for a possible role for serotonergic drugs in the management of behavioral disturbances in people with dementia, further trials are desirable. In addition to being larger and longer-term, future trials need to involve a wider diversity of dementia types and to use established measures to evaluate behavioral disturbances in dementia so as to facilitate pooling of data. Furthermore, a more detailed description of symptoms would be useful in determining whether specific features respond differently to treatment. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-04-18 14:53:57 +0100" MODIFIED_BY="Helen Collins">
<P>We are grateful to Dr. Florence Lebert, Dr. Myron F Weiner and Professor Brian Lawlor for providing additional data needed for this review. Thanks are also due to Dr Reem Malouf of the Cochrane Dementia and Cognitive Improvement Group for her help with completing the analysis and performing the 2008 update, and to Ann Buckley for her contributions as consumer editor.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>GMT: drafting of review versions; all correspondence; selection of trials; extraction of data; entry of data; interpretation of data analyses; updating review<BR/>JGE: drafting of review versions; selection of trials; extraction of data; interpretation of data analyses<BR/>MF: drafting of review versions; selection of trials; extraction of data; interpretation of data analyses</P>
<P>Contact editor: Rupert McShane<BR/>Consumer editor: Ann Buckley</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-04-18 15:09:44 +0100" MODIFIED_BY="Helen Collins">
<STUDIES MODIFIED="2008-04-18 14:58:15 +0100" MODIFIED_BY="Helen Collins">
<INCLUDED_STUDIES MODIFIED="2008-04-04 15:54:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Lebert-2004" MODIFIED="2008-04-04 15:54:50 +0100" MODIFIED_BY="[Empty name]" NAME="Lebert 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lebert F, Pasquier F, Stekke W</AU>
<TI>Double blind placebo controlled trial of trazodone in patients with fronto-temporal dementia</TI>
<SO>Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva</SO>
<YR>2002</YR>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lebert F, Stekke W, Hasenbroekx C, Pasquier F</AU>
<TI>Frontotemporal dementia: a randomised, controlled trial with trazodone</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>4</NO>
<PG>355-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-04 15:54:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebert F, Stekke W, Hasenbroekx C, Pasquier F</AU>
<TI>Trazodone in fronto-temporal dementia</TI>
<SO>Research and Practice in Alzheimer's Disease</SO>
<YR>2006</YR>
<VL>11</VL>
<PG>356-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-04 15:52:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebert F</AU>
<TI>Behavioral benefits of trazodone are sustained for the long term in frontotemporal dementia</TI>
<SO>Therapy</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>1</NO>
<PG>93-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teri-2000" NAME="Teri 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ and members of the Alzheimer's Disease Cooperative Study</AU>
<TI>Treatment of Agitation in Alzheimer's disease: a randomized, placebo-controlled clinical trial</TI>
<SO>Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. 2000 April 5-8, Stockholm, Sweden</SO>
<YR>2000a</YR>
<PG>153</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL,Scheneider LS, Sano M, Whitehouse P,Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ</AU>
<TI>Treatment of agitation in AD: A randomized, placebo-controlled clinical trial</TI>
<SO>Neurology</SO>
<YR>2000b</YR>
<VL>55</VL>
<NO>9</NO>
<PG>1271-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Thal L, Alzheimer's Disease Cooperative Study</AU>
<TI>Agitation in Alzheimer's Disease</TI>
<SO>Alzheimer's Disease Education and Referral Center (ADEAR)</SO>
<YR>1999d</YR>
<PB>ADEAR</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;12 months follow-up data from a 4 month randomized study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiner MF, Tractenberg RE, Sano M, Logsdon R, Teri L, Galasko D, Gamst A, Thomas R, Thal LJ</AU>
<TI>No long term effect of behavioural treatment of psychotropic drug use for agitation in Alzheimer's Disease Patients.</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>95-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-04-18 14:58:15 +0100" MODIFIED_BY="Helen Collins">
<STUDY DATA_SOURCE="PUB" ID="STD-Lawlor-1991" NAME="Lawlor 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;m-CPP(a serotonin agonist and  principal metabolite of trazodone) versus placebo&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lawlor BA, Sunderland T, Mellow AM, Molchan SE, Martinez R, Murphy DL</AU>
<TI>A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease.</TI>
<SO>Biological Psychiatry</SO>
<YR>1991</YR>
<VL>30</VL>
<NO>2</NO>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawlor-1994" MODIFIED="2008-04-18 14:57:13 +0100" MODIFIED_BY="Helen Collins" NAME="Lawlor 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Comments on the article by W. J. Burke about the use of selective serotonin reuptake inhibitors  for depression and psychosis complicating dementia. Burke state that both trazodone and buspirone  have not been teste in a double blind study , and that is incorrect. The authors reported a pilot study in a previous article. (Lawlor 1994)&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Lawlor B</AU>
<TI>The use of selective serotonin reuptake inhibitors for depression and psychosis complication dementia [Comment]</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>7</NO>
<PG>496</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-18 14:57:13 +0100" MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lawlor BA, Radcliffe J, Molchan SE, Martinez RA, Hill JL, Sunderland T</AU>
<TI>A pilot placebo-controlled study of trazodone and buspirone in Alheimer's disease</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>1</NO>
<PG>55-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez_x002d_Pousa-2007" MODIFIED="2008-04-18 14:57:30 +0100" MODIFIED_BY="Helen Collins" NAME="Lopez-Pousa 2007" YEAR="">
<REFERENCE MODIFIED="2008-04-18 14:57:30 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Pousa S, Garre-Olmo J, Vilalta-Franch J, Turon-Estrada, Pericot-Nierga I</AU>
<TI>Trazodone for Alzheimer's disease: A naturalistic follow-up study</TI>
<SO>Archive of Gerontology Geriatrics</SO>
<YR>2007</YR>
<VL>24</VL>
<PG>0167-4943</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mervis-1991" MODIFIED="2008-04-18 14:57:41 +0100" MODIFIED_BY="Helen Collins" NAME="Mervis 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-04-18 14:57:41 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mervis RJ, Ganzell S, Fitten LJ, Daum G, Tripodis K, Takayesu S</AU>
<TI>Comparison of Carbamazepine and Trazodone in the control of aggression / agitation in demented institutionalized patients</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>8</NO>
<PG>A75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Passeri-1993" MODIFIED="2008-04-18 14:57:55 +0100" MODIFIED_BY="Helen Collins" NAME="Passeri 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-04-18 14:57:55 +0100" MODIFIED_BY="Helen Collins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, et al</AU>
<TI>Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study</TI>
<SO>Aging Clinical and Experimental Research</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>1</NO>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sauvage-1987" NAME="Sauvage 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Randomized double-blind study  trazodone vs amitriptyline. Dementia is a exclusion criteria&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sauvage PH, Hessel L, Michel JP</AU>
<TI>[Double-blind study of trazodone versus amitriptyline in geriatry]</TI>
<TO>Etude en double-insu de la trazadone contre l'amitriptyline en milieu geriatrique</TO>
<SO>Psychologie Medicale</SO>
<YR>1987</YR>
<VL>19</VL>
<NO>8</NO>
<PG>1357-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sultzer-1997" NAME="Sultzer 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Randomized double blind  study . Trazodone vs Haloperidol. no placebo control group&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sultzer DL, Gray KF, Gunay I, Berisford A, Mahler ME</AU>
<TI>A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>1</NO>
<PG>60-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sultzer-2001" MODIFIED="2008-04-18 14:58:15 +0100" MODIFIED_BY="Helen Collins" NAME="Sultzer 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sultzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME</AU>
<TI>Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?</TI>
<SO>Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26. San Francisco.</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-18 14:58:15 +0100" MODIFIED_BY="Helen Collins" NOTES="&lt;p&gt;Randomized double-blind . trazodone vs Haloperidol. No placebo control group&lt;/p&gt;" NOTES_MODIFIED="2008-04-18 14:58:15 +0100" NOTES_MODIFIED_BY="Helen Collins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sultzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME</AU>
<TI>Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>10</NO>
<PG>1294-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-04-18 15:09:44 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES MODIFIED="2008-04-18 15:09:44 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders</SO>
<YR>1994</YR>
<EN>IV</EN>
<PB>American Psychiatric Publishing</PB>
<CY>Washington DC, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bains-2004" MODIFIED="2008-04-18 14:59:10 +0100" MODIFIED_BY="Helen Collins" NAME="Bains 2004" TYPE="COCHRANE_REVIEW">
<AU>Bains J, Birks JS, Dening TR</AU>
<TI>Antidepressants for treating depression in dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-1999" MODIFIED="2008-04-18 14:59:35 +0100" MODIFIED_BY="Helen Collins" NAME="Ballard 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ballard C</AU>
<TI>Treating behavioural and psychological signs in Alzheimer's disease.The evidence for current pharmacological treatments is not strong</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>138-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brogden-1981" MODIFIED="2008-04-18 14:59:46 +0100" MODIFIED_BY="Helen Collins" NAME="Brogden 1981" TYPE="JOURNAL_ARTICLE">
<AU>Brogden RN, Heel RC, Speight RM</AU>
<TI>Trazodone: A review of its pharmacological properties and therapeutic uses in depression and anxiety</TI>
<SO>Drugs</SO>
<YR>1981</YR>
<VL>21</VL>
<PG>401-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H, Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Class-1997" MODIFIED="2008-04-18 14:59:54 +0100" MODIFIED_BY="Helen Collins" NAME="Class 1997" TYPE="JOURNAL_ARTICLE">
<AU>Class CA, Schneider L, Farlow MR</AU>
<TI>Optimal management of behavioural disorders associated with dementia.</TI>
<SO>Drugs and Aging</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>95-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen_x002d_Mansfield-1986" MODIFIED="2008-04-18 15:00:20 +0100" MODIFIED_BY="Helen Collins" NAME="Cohen-Mansfield 1986" TYPE="JOURNAL_ARTICLE">
<AU>Cohen-Mansfield J</AU>
<TI>Agitated behaviors in the elderly, I: a conceptual review</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1986</YR>
<VL>34</VL>
<PG>711-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen_x002d_Mansfield-1989" MODIFIED="2008-04-18 15:00:30 +0100" MODIFIED_BY="Helen Collins" NAME="Cohen-Mansfield 1989" TYPE="JOURNAL_ARTICLE">
<AU>Cohen-Mansfiel J, Marx MS, Rosenthal AS</AU>
<TI>A description of agitation in a nursing home</TI>
<SO>Journal of Gerontology</SO>
<YR>1989</YR>
<VL>44</VL>
<PG>M77-M84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen_x002d_Mansfield-1996" MODIFIED="2008-04-18 15:00:45 +0100" MODIFIED_BY="Helen Collins" NAME="Cohen-Mansfield 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cohen-Mansfield J</AU>
<TI>Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instruments</TI>
<SO>International Psychogeriatrics</SO>
<YR>1996</YR>
<VL>3 (suppl 8)</VL>
<PG>309-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen_x002d_Mansfield-1998" MODIFIED="2008-04-18 15:00:06 +0100" MODIFIED_BY="Helen Collins" NAME="Cohen-Mansfield 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cohen-Mansfield J, Werner P</AU>
<TI>Predictors of aggressive behaviors: a longitudinal study in senior day care centers</TI>
<SO>Journals of Gerontology Series B Psychological Sciences and Social Sciences</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>5</NO>
<PG>300-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CSM-2004" NAME="CSM 2004" TYPE="OTHER">
<AU>Committee on Safety of Medicines</AU>
<TI>Atypical antipsychotic drugs and stroke</TI>
<SO>http://www.mhra.gov.uk/</SO>
<YR>2004</YR>
<PG>CEM/CMO/2004/1.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cummings-1994" MODIFIED="2008-04-18 15:00:59 +0100" MODIFIED_BY="Helen Collins" NAME="Cummings 1994" TYPE="JOURNAL_ARTICLE">
<AU>Cummings Jl, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gobiern J</AU>
<TI>The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<PG>2308-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devanand-1996" MODIFIED="2008-04-18 15:01:11 +0100" MODIFIED_BY="Helen Collins" NAME="Devanand 1996" TYPE="JOURNAL_ARTICLE">
<AU>Devanand DP</AU>
<TI>Do the Symptoms respond to treatment-pharmacologic or nonpharmacologic? Antipsychotic treatment in outpatients with dementia</TI>
<SO>International Psychogeriatrics</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>Suppl 3</NO>
<PG>355-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elon-1992" MODIFIED="2008-04-18 15:01:24 +0100" MODIFIED_BY="Helen Collins" NAME="Elon 1992" TYPE="JOURNAL_ARTICLE">
<AU>Elon R, Pawlson LG</AU>
<TI>The impact of OBRA on medical practice within nursing facilities</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1992</YR>
<VL>40</VL>
<PG>958-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finkel-2000" MODIFIED="2008-04-18 15:01:32 +0100" MODIFIED_BY="Helen Collins" NAME="Finkel 2000" TYPE="JOURNAL_ARTICLE">
<AU>Finkel SI, Burns A</AU>
<TI>Behavioural and psychological symptoms of dementia (BPSD): a clinical and research update</TI>
<SO>International Psychogeriatrics</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folstein-1975" MODIFIED="2008-04-18 15:01:40 +0100" MODIFIED_BY="Helen Collins" NAME="Folstein 1975" TYPE="JOURNAL_ARTICLE">
<AU>Folstein MF, Folstein SE, McHugh PR</AU>
<TI>Mini-mental state: a practical method for grading the cognitive state of patients for the clinician</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1975</YR>
<VL>12</VL>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galluzi-2000" MODIFIED="2008-04-18 15:01:48 +0100" MODIFIED_BY="Helen Collins" NAME="Galluzi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Galluzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB</AU>
<TI>Coma in a patient with Alzheimer's disease taking low dose trazodone and ginkgo biloba</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>2000</YR>
<VL>68</VL>
<NO>5</NO>
<PG>679-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gottfries-1991" MODIFIED="2008-04-18 15:02:02 +0100" MODIFIED_BY="Helen Collins" NAME="Gottfries 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gottfries CG, Nyth AC</AU>
<TI>Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia</TI>
<SO>Annals of the Academy of Sciences of the USA</SO>
<YR>1991</YR>
<VL>640</VL>
<PG>276-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenwald-1986" MODIFIED="2008-04-18 15:02:15 +0100" MODIFIED_BY="Helen Collins" NAME="Greenwald 1986" TYPE="JOURNAL_ARTICLE">
<AU>Greenwald BS, Silverman SM</AU>
<TI>Serotoninergic treatment of screaming and banging in dementia</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>2</VL>
<PG>1464-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Houlihan-1994" MODIFIED="2008-04-18 15:02:23 +0100" MODIFIED_BY="Helen Collins" NAME="Houlihan 1994" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan DJ, Mulsant BH, Sweet RA, Rifai AH, Pasternak R, Rosen J, et al</AU>
<TI>A naturalistic study of trazodone in the treatment of behavioral complications of dementia</TI>
<SO>The American Journal of Geriatric Psychiatry</SO>
<YR>1994</YR>
<VL>2</VL>
<NO>1</NO>
<PG>78-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1982" MODIFIED="2008-04-18 15:02:40 +0100" MODIFIED_BY="Helen Collins" NAME="Hughes 1982" TYPE="JOURNAL_ARTICLE">
<AU>Hughes CP, Berg L, Danzinger WL, Coben LA, Martin RL</AU>
<TI>A new clinical scale for the staging of dementia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>140</VL>
<PG>566-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahn-1991" MODIFIED="2008-04-18 15:02:51 +0100" MODIFIED_BY="Helen Collins" NAME="Kahn 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kahn RS, Wetzler S</AU>
<TI>m-Chlorophenylpiperazine as a probe of serotonin function</TI>
<SO>Biological Psychiatry</SO>
<YR>1991</YR>
<VL>30</VL>
<PG>1139-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koss-1997" MODIFIED="2008-04-18 15:03:13 +0100" MODIFIED_BY="Helen Collins" NAME="Koss 1997" TYPE="JOURNAL_ARTICLE">
<AU>KossE, Weiner M, Ernesto C</AU>
<TI>Assessing patterns of agitation in Alzheimer's disease patients with the Cohen Mansfield Agitation Inventroy</TI>
<SO>Alzheimer's Disease and Associated Disorders</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>545-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lanctot-1998" MODIFIED="2008-04-18 15:03:23 +0100" MODIFIED_BY="Helen Collins" NAME="Lanctot 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lanctot KL, Best TS, Mittmann N, Liu BA, Oh PI, Einarson TR, Naranjo CA</AU>
<TI>Efficacy and safety of neuroleptics in behavioral disorders associated with dementia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>10</NO>
<PG>550-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawlor-1989" MODIFIED="2008-04-18 15:03:36 +0100" MODIFIED_BY="Helen Collins" NAME="Lawlor 1989" TYPE="JOURNAL_ARTICLE">
<AU>Lawlor BA, Sunderland T, Melllow AM, HIll JL, Molchan SE, Murphy DL</AU>
<TI>Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease: A controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<PG>542-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawton-1969" MODIFIED="2008-04-18 15:03:46 +0100" MODIFIED_BY="Helen Collins" NAME="Lawton 1969" TYPE="JOURNAL_ARTICLE">
<AU>Lawton MP, Brody EM</AU>
<TI>Assessment of older people: Self-maintaining and instrumental activities for daily living</TI>
<SO>Gerontologist</SO>
<YR>1969</YR>
<VL>9</VL>
<PG>179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lebert-1994" MODIFIED="2008-04-18 15:03:54 +0100" MODIFIED_BY="Helen Collins" NAME="Lebert 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lebert F, Pasquier F, Petit H</AU>
<TI>Behavioral effects of trazodone in Alzheimer's disease</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<PG>536-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehmann-1975" NAME="Lehmann 1975" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann HE, Ban TA, Schwartz GV</AU>
<TI>Psychotherapeutic profile of a new psychoactive drug trazodone (AF-1161)</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1975</YR>
<VL>10</VL>
<NO>1</NO>
<PG>42-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-1994" MODIFIED="2008-04-18 15:04:10 +0100" MODIFIED_BY="Helen Collins" NAME="Levy 1994" TYPE="JOURNAL_ARTICLE">
<AU>Levy MA, Burgio LD, Sweet R, Bonino P, Janosky J, Perel J</AU>
<TI>A trial of buspirone for the control of disruptive behaviors in community-dwelling patients with dementia</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>841-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Logsdon-1999" MODIFIED="2008-04-18 15:04:18 +0100" MODIFIED_BY="Helen Collins" NAME="Logsdon 1999" TYPE="JOURNAL_ARTICLE">
<AU>Logsdon RG, Teri L, Weiner MF</AU>
<TI>Assessment of agitation in Alzheimer's Disease: the Agitated Behavior in Dementia Scale</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1999</YR>
<VL>47</VL>
<PG>1354-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lonergan-2004" MODIFIED="2008-04-18 15:04:41 +0100" MODIFIED_BY="Helen Collins" NAME="Lonergan 2004" TYPE="COCHRANE_REVIEW">
<AU>Lonergan E, Luxenberg J, Colford J</AU>
<TI>Haloperidol for agitation in dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lund-Manchester-1994" MODIFIED="2008-04-18 15:04:54 +0100" MODIFIED_BY="Helen Collins" NAME="Lund Manchester 1994" TYPE="OTHER">
<AU>The Lund and Manchester Groups</AU>
<TI>The Lund and Manchester Groups: Consensus Statement. Clinical and neuropathological criteria for frontotemporal dementia</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1994</YR>
<VL>57</VL>
<PG>416-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1984" MODIFIED="2008-04-18 15:05:07 +0100" MODIFIED_BY="Helen Collins" NAME="McKhann 1984" TYPE="JOURNAL_ARTICLE">
<AU>McKhann G, Drachman D, Folstein M, Katzman R, Price D,Stadlem E</AU>
<TI>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McShane-1998" MODIFIED="2008-04-18 15:05:17 +0100" MODIFIED_BY="Helen Collins" NAME="McShane 1998" TYPE="JOURNAL_ARTICLE">
<AU>McShane R, Keene J, Fairburn C, Jacoby R, Hope T</AU>
<TI>Psychiatric symptoms in patients with dementia predict the later development of behavioural abnormalities</TI>
<SO>Psychological Medicine</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>5</NO>
<PG>1119-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mintzer-2001" MODIFIED="2008-04-18 15:05:33 +0100" MODIFIED_BY="Helen Collins" NAME="Mintzer 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mintzer JE</AU>
<TI>Underlying mechanisms of pychosis and aggression in patients with Alzheimer's Disease</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>Suppl 21</NO>
<PG>23-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nair-1973" MODIFIED="2008-04-18 15:05:37 +0100" MODIFIED_BY="Helen Collins" NAME="Nair 1973" TYPE="JOURNAL_ARTICLE">
<AU>Nair NP, Ban TA, Hontela S, Clarke R</AU>
<TI>Trazodone in the treatment of organic brain syndromes, with special reference to psychogeriatrics</TI>
<SO>Current Therapeutic Research and Clinical Experiment</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>10</NO>
<PG>769-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Neill-1986" MODIFIED="2008-04-18 15:05:48 +0100" MODIFIED_BY="Helen Collins" NAME="O'Neill 1986" TYPE="JOURNAL_ARTICLE">
<AU>O'Neill M, Page N, Adkins WN, Eichetman B</AU>
<TI>Tryptophan-trazodone treatment of aggressive behavior</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>ii</VL>
<PG>859-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Passeri-1993a" MODIFIED="2008-04-04 10:54:19 +0100" MODIFIED_BY="Helen Collins" NAME="Passeri 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, et al</AU>
<TI>Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of adouble-blind multicenter study</TI>
<SO>Aging Clinical and Experimental Research</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>1</NO>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pinner-1988" MODIFIED="2008-04-18 15:06:05 +0100" MODIFIED_BY="Helen Collins" NAME="Pinner 1988" TYPE="JOURNAL_ARTICLE">
<AU>Pinner E, Rich CL</AU>
<TI>Effects of trazodone on aggressive behavior in seven patients with organic mental disorders</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<PG>1295-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reisberg-1982" MODIFIED="2008-04-18 15:06:11 +0100" MODIFIED_BY="Helen Collins" NAME="Reisberg 1982" TYPE="JOURNAL_ARTICLE">
<AU>Reisberg B, Ferris SH, De Leon MJ, Crook T</AU>
<TI>The Global Deterioration Scale (GDS) for assessment of primary degenerative dementia.</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>1136-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sakauye-1993" MODIFIED="2008-04-18 15:06:18 +0100" MODIFIED_BY="Helen Collins" NAME="Sakauye 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sakauye KM, Camp CJ, Ford PA</AU>
<TI>Effects of buspirone on agitation associated with dementia</TI>
<SO>The American Journal of Geriatric Psychiatry</SO>
<YR>1993</YR>
<VL>1</VL>
<NO>1</NO>
<PG>82-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salzman-2001" NAME="Salzman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Salzman C</AU>
<TI>Treatment of the agitation of late life psychosis and Alzheimer's disease</TI>
<SO>European Psychiatry</SO>
<YR>2001</YR>
<VL>16, suppl 1</VL>
<PG>25s-8s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1989" MODIFIED="2008-04-18 15:06:53 +0100" MODIFIED_BY="Helen Collins" NAME="Schneider 1989" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Gleason RP, Chui HC</AU>
<TI>Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>109-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1990" MODIFIED="2008-04-18 15:07:02 +0100" MODIFIED_BY="Helen Collins" NAME="Schneider 1990" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Pollock VE, Lyness SA</AU>
<TI>A Metaanalysis of controlled trials of neuroleptic treatment in dementia</TI>
<SO>Journal of American Geriatrics Society</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>5</NO>
<PG>553-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1991" MODIFIED="2008-04-18 15:07:41 +0100" MODIFIED_BY="Helen Collins" NAME="Schneider 1991" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Sobin PB</AU>
<TI>Non neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>10</NO>
<PG>691-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1997" NAME="Schneider 1997" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Olin JT, Doody RS</AU>
<TI>Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change</TI>
<SO>Alzheimer's Disease and Associated Disorders</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>S22-S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1999" NAME="Schneider 1999" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS</AU>
<TI>Pharmacologic management of psychosis in dementia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60 (suppl 8)</VL>
<PG>54-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shorr-1994" MODIFIED="2008-04-18 15:08:02 +0100" MODIFIED_BY="Helen Collins" NAME="Shorr 1994" TYPE="CORRESPONDENCE">
<AU>Shorr RI, Fought Rl, Ray WA</AU>
<TI>Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1994</YR>
<VL>271</VL>
<PG>358-362</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1986" MODIFIED="2008-04-18 15:08:14 +0100" MODIFIED_BY="Helen Collins" NAME="Simpson 1986" TYPE="JOURNAL_ARTICLE">
<AU>Simpson DM, Foster D</AU>
<TI>Improvement in organically disturbed behavior with trazodone treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<PG>191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tariot-1995" MODIFIED="2008-04-18 15:08:31 +0100" MODIFIED_BY="Helen Collins" NAME="Tariot 1995" TYPE="JOURNAL_ARTICLE">
<AU>Tariot P, Mack J, Patterson M and Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease</AU>
<TI>The Behavior Rating Scale of the Consortium to Establish a Registry for Alzheimer's Disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>1349-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teri-1992" MODIFIED="2008-04-18 15:08:43 +0100" MODIFIED_BY="Helen Collins" NAME="Teri 1992" TYPE="JOURNAL_ARTICLE">
<AU>Teri L, Truax P, Logsdon RG, Uomoto J, Zarit S, Vitaliano PP</AU>
<TI>Assesmentt of behavioral problems in dementia: the Revised Memory and Behavior Problems Checklist</TI>
<SO>Psychology and Aging</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>622-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tingle-1986" MODIFIED="2008-04-18 15:08:52 +0100" MODIFIED_BY="Helen Collins" NAME="Tingle 1986" TYPE="JOURNAL_ARTICLE">
<AU>Tingle D</AU>
<TI>Trazodone in dementia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>9</NO>
<PG>482-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vitaliano-1991" NAME="Vitaliano 1991" TYPE="JOURNAL_ARTICLE">
<AU>Vitaliano PP, Russo J, Young HM, Becker J, Maiuro RD</AU>
<TI>The screen for caregiver burden</TI>
<SO>Gerontologist</SO>
<YR>1991</YR>
<VL>31</VL>
<PG>76-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiner-2002" MODIFIED="2008-04-18 15:09:13 +0100" MODIFIED_BY="Helen Collins" NAME="Weiner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Weiner MF, Tractenber RE, Sano M, Logsdon R, Teri L, Galasko D, et al</AU>
<TI>No long term effect of behavioural treatment of psychotropic drug use for agitation in Alzheimer's disease</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehouse-1995" MODIFIED="2008-04-18 15:09:23 +0100" MODIFIED_BY="Helen Collins" NAME="Whitehouse 1995" TYPE="JOURNAL_ARTICLE">
<AU>Whitehouse PJ, Voci J</AU>
<TI>Therapeutic trials in Alzheimer's disease</TI>
<SO>Current Opinion in Neurology</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>4</NO>
<PG>275-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilcock-1987" MODIFIED="2008-04-18 15:09:34 +0100" MODIFIED_BY="Helen Collins" NAME="Wilcock 1987" TYPE="JOURNAL_ARTICLE">
<AU>Wilcock GK, Stevens J, Perkins A</AU>
<TI>Trazodone/tryptophan for aggressive behaviour</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>929-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeager-1995" MODIFIED="2008-04-18 15:09:44 +0100" MODIFIED_BY="Helen Collins" NAME="Yeager 1995" TYPE="JOURNAL_ARTICLE">
<AU>Yeager BF, Farnett LE, Ruzicka SA</AU>
<TI>Management of the behavioral manifestations of dementia (review article)</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<NO>3</NO>
<PG>250-60</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-04-04 11:01:16 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Martinon_x002d_Torres-2004" MODIFIED="2008-04-04 11:01:16 +0100" MODIFIED_BY="Helen Collins" NAME="Martinon-Torres 2004" TYPE="COCHRANE_REVIEW">
<AU>Martinon-Torres G, Fioravanti M, Grimley Evans J</AU>
<TI>Trazodone for agitation in dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-04-04 11:01:16 +0100" MODIFIED_BY="Helen Collins">
<IDENTIFIER MODIFIED="2008-04-04 11:01:16 +0100" MODIFIED_BY="Helen Collins" TYPE="DOI" VALUE="10.1002/14651858.CD004990"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-04-18 15:14:37 +0100" MODIFIED_BY="Helen Collins">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-04-18 15:14:37 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-04-18 14:54:15 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Lebert-2004">
<CHAR_METHODS>
<P>12 weeks, multicentre randomized, double-blind, placebo-controlled trial with a cross-over design.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-18 14:54:15 +0100" MODIFIED_BY="Helen Collins">
<P>Country: France, Belgium<BR/>31 outpatients (16F; 15M)<BR/>Mean age 61.7 years<BR/>-Dementia evaluation:<BR/>FrontoTemporal Dementia (FTD) according to the Lund and Manchester Group<BR/>-Behavioural evaluation:NPI (total score &gt;8 and a score&gt;=4 for one of the following items:delusions, hallucinations, aggression, depression/dysphoria, anxiety, disinhibition, irritability, abnormal motor behaviour or sleep disorders.<BR/>-No previous neurological and psychiatric history.<BR/>Exclusion Criteria:<BR/>1.Major depression. 2. Evidence of addiction and neuroleptics or antidepressant agents taken within 4 weeks preceding the assessment. 3. Poorly controlled concomitant illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Trazodone (range 50 to 300 mg /day)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Behavioural disturbances:<BR/>NPI score<BR/>-Clinical Global Impression Improvement (CGI-I)<BR/>-MMSE<BR/>-Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>There was a significant decrease in the NPI total score with trazodone (P = 0.028)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-04-18 14:54:47 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Teri-2000">
<CHAR_METHODS>
<P>16 weeks, multicentre, randomized, placebo-controlled, double-blind, parallel-group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-04-18 14:54:35 +0100" MODIFIED_BY="Helen Collins">
<P>Country: USA<BR/>149 patients from ADCS sites and their caregivers. Mean age: 73.2 (6.6) (trazodone); 75.3 (6.9) (haloperidol); 74.8 (8.4) (BMT); 75.8 (6.2) (placebo).<BR/>Gender: 41% (trazodone); 59% (haloperidol); 54% (BMT);67% (placebo)<BR/>Selection criteria<BR/>-Dementia evaluation: Alzheimer's Disease according to NINCDS -ADRDA criteria.<BR/>-Behavioural evaluation: at least 2 weeks history of two or more agitated behaviours occurring at least once weekly.<BR/>2 weeks without psychotropic medications.ABID, ADCS-CGIC,BRSD, CMAI<BR/>-Caregiver participants: spouse or adult relative who had a minimum of 5 hours per day contact with<BR/>Exclusion criteria:<BR/>1.Major psychiatric disorders within the last 2 years. 2.Neurologic or systemic illness (e.g. delirium,hypoxia, or unstable thyroid dysfunction) 3.Alcohol or drug abuse within the past year. 4.Need for emergency treatment for agitation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Trazodone (range 50 to 300mg/d, mean dose 200 mg/d) (N=37)<BR/>2. Haloperidol (range 0 to 3 mg/d, mean dose 1.8 mg/d) (N=34)<BR/>3. BMT: 8 weekly and 3 biweekly sessions that provide information about Alzheimer's Disease, strategies for decreasing agitated behaviours, and structured in-session and out-of-session assignments, including the use of a video tape training program.(N=41)<BR/>4. Placebo (N=36)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-04-18 14:54:47 +0100" MODIFIED_BY="Helen Collins">
<P>1.Primary outcome: ADCS-CGIC<BR/>2.Secondary outcomes:<BR/>-Behavioural disturbances: CERAD-BRSD, RMBPC, CMAI, ABID<BR/>-Functional disturbance: Physical Self-Maintenance and Instrumental Activities of Daily Living.<BR/>-Cognitive Function: MMSE<BR/>-Caregiver burden and reactivity to disruptive behaviours: SCB, RMBPC<BR/>-Adverse symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No significant differences on outcome were obtained between haloperidol, trazodone, BMT, or placebo. 34% of participants improved relative to baseline. Significantly fewer adverse events of bradykinesia and parkinsonian gait were evident in the BMT arm. Symptoms did not respond differentially to the different treatments. Comparable modest reductions in agitation occurred in patients receiving haloperidol, trazodone, BMT and placebo. More effective pharmacologic, nonpharmacologic, and combination treatments are needed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ABID: Agitated Behavior Inventory for Dementia (<LINK REF="REF-Logsdon-1999" TYPE="REFERENCE">Logsdon 1999</LINK>)<BR/>ADCS-CGIC: Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (<LINK REF="REF-Schneider-1997" TYPE="REFERENCE">Schneider 1997</LINK>)<BR/>BPRS: Brief Psychiatric Rating Scale (Overall 1962)<BR/>CERAD-BRSD: The Consortium to Establish a Registry for Alzheimer's Disease Behavioral Rating Scale for Dementia (<LINK REF="REF-Tariot-1995" TYPE="REFERENCE">Tariot 1995</LINK>)<BR/>CMAI: Cohen-Mansfield Agitation Inventory (<LINK REF="REF-Koss-1997" TYPE="REFERENCE">Koss 1997</LINK>)<BR/>DMAS: Dementia Mood Assessment Scale (Sunderland 1988)<BR/>GDS: Global Deterioration Scale (<LINK REF="REF-Reisberg-1982" TYPE="REFERENCE">Reisberg 1982</LINK>)<BR/>MMSE: Mini-Mental State Examination (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>)<BR/>NINCDS-ADRDA: National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (<LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>)<BR/>RMBPC: Revised Memory and Behavior Problem Checklist (<LINK REF="REF-Teri-1992" TYPE="REFERENCE">Teri 1992</LINK>)<BR/>SCB: Screen for Caregiver Burden (<LINK REF="REF-Vitaliano-1991" TYPE="REFERENCE">Vitaliano 1991</LINK>)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-04-18 14:55:45 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-04-18 14:55:13 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Lawlor-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-18 14:55:13 +0100" MODIFIED_BY="Helen Collins">
<P>The study compared m-CPP (meta-chlorophenylpiperazine), a metabolite of trazodone versus placebo in agitated Alzheimer's disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lawlor-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-over design. The patients randomly received one drug in each phase. The trial does not compare placebo with trazodone at the same phase.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-04 15:59:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez_x002d_Pousa-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-04 15:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>An observational study on patients with probable Alzheimer's disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mervis-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo control group. The study compared trazodone versus carbamazepine in agitated dementia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-18 14:55:45 +0100" MODIFIED_BY="Helen Collins" STUDY_ID="STD-Passeri-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-18 14:55:45 +0100" MODIFIED_BY="Helen Collins">
<P>No placebo control group. Outcomes limited to depressive symptoms. The study compared the effect of trazodone versus 5'-methyltetrahydrofolic acid in elderly patients with dementia and depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sauvage-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo control group and dementia is an exclusion criterion. The study compared the effect of trazodone versus amitriptyline in geriatrics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sultzer-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo control group. The study compared the effect of trazodone versus haloperidol on agitated dementia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sultzer-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo control group. The study compared the effect of trazodone versus haloperidol on agitated dementia. The trial examined the relationship between behavioural improvement and co-occurring psychosis or mood symptoms who were treated with either haloperidol or trazodone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-04-18 14:54:53 +0100" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-04-18 14:54:53 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-18 14:54:22 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Lebert-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-04-18 14:54:53 +0100" MODIFIED_BY="Helen Collins" RESULT="UNKNOWN" STUDY_ID="STD-Teri-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-04-18 15:15:08 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-04-18 14:55:57 +0100" MODIFIED_BY="Helen Collins" NO="1">
<TITLE>Baseline characteristics of the included trials</TITLE>
<TABLE COLS="10" ROWS="3">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>country</P>
</TH>
<TH>
<P>population</P>
</TH>
<TH>
<P>diagnosis criteria</P>
</TH>
<TH>
<P>gender</P>
</TH>
<TH>
<P>mean age</P>
</TH>
<TH>
<P>study design</P>
</TH>
<TH>
<P>intervention</P>
</TH>
<TH>
<P>dose</P>
</TH>
<TH>
<P>MMSE mean</P>
</TH>
</TR>
<TR>
<TD>
<P>Teri 2000</P>
</TD>
<TD>
<P>USA</P>
</TD>
<TD>
<P>148 outpatients (ADCS sites)</P>
</TD>
<TD>
<P>Alzheimer's Disease (NINDSC-ADRDA); Behaviour evaluation: CERAD-BRSD, CMAI, ABID, RMBPC; Functional: PSM, IADL; Caregiver burden:SCB</P>
</TD>
<TD>
<P>41% F(trazodone), 67%F (placebo), 59%F (haloperidol), 54%F (BMT)</P>
</TD>
<TD>
<P>73.2(6.6) trazodone, 75.8 (6.2) placebo, 75.3(6.9) haloperidol, 74.8(8.4) BMT</P>
</TD>
<TD>
<P>parallel</P>
</TD>
<TD>
<P>16 weeks.Trazodone (N=37), placebo (N=36), haloperidol (N=34), BMT (N=41)</P>
</TD>
<TD>
<P>Range 50 mg to 300 mg daily, mean dose 200+/- 75 mg/day</P>
</TD>
<TD>
<P>14 (7)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lebert 2004</P>
</TD>
<TD>
<P>France and Belgium</P>
</TD>
<TD>
<P>31 outpatients</P>
</TD>
<TD>
<P>Frontotemporal Dementia (Lund and Manchester group criteria); NPI total&gt;8 and &gt;=4 for one items: hallucinations, delusion, aggression, depression/dysphoria, anxiety, disinhibition, irritability, abnormal motor behaviour or sleep disorders. NPI baseline: 53 (17.9)</P>
</TD>
<TD>
<P>16 F (51.6%) 15 M (48.4%)</P>
</TD>
<TD>
<P>61.7 years</P>
</TD>
<TD>
<P>cross-over</P>
</TD>
<TD>
<P>Two 6-week periods. Two sequences (placebo-trazodone or trazodone-placebo).No washout period . First phase: trazodone (N=15) placebo (N=16)</P>
</TD>
<TD>
<P>Range 50 to 300 mg/day</P>
</TD>
<TD>
<P>20.8 (8.3)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-04-18 14:56:05 +0100" MODIFIED_BY="Helen Collins" NO="2">
<TITLE>Outcome measures</TITLE>
<TABLE COLS="3" ROWS="3">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Primary outcome</P>
</TH>
<TH>
<P>Secondary outcome</P>
</TH>
</TR>
<TR>
<TD>
<P>Teri 2000</P>
</TD>
<TD>
<P>Clinical Global Impression of Change (ADCS-CGIC)</P>
</TD>
<TD>
<P>1. Behaviour: CERAD-Behaviour Rating Scale for Dementia (CERAD-BRSD), Cohen-Mansfield Agitation Inventory (CMAI), Agitated Behavior Inventory for Dementia (ABID). 2. Functional: Physical Self Maintenance and Instrumental Activities of Daily Living. 3. Cognition:Mini-Mental State Examination (MMSE). 4.Caregiver burden: the Screen for Caregiver Burden (SCB), The Revised Memory and Behavior Problem Checklist (RMBPC)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lebert 2004</P>
</TD>
<TD>
<P>Neuropsychiatric Inventory (NPI)</P>
</TD>
<TD>
<P>Clinical Global Impression Improvement (CGI-I) and Mini-Mental State Examination (MMSE)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-04-18 15:15:08 +0100" MODIFIED_BY="Helen Collins" NO="3">
<TITLE>Rating Scales</TITLE>
<TABLE COLS="5" ROWS="11">
<TR>
<TH>
<P>Evaluation</P>
</TH>
<TH>
<P>Abbreviation</P>
</TH>
<TH>
<P>Name</P>
</TH>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Reference</P>
</TH>
</TR>
<TR>
<TD>
<P>Global Assessment</P>
</TD>
<TD>
<P>ADCS-CGIC</P>
</TD>
<TD>
<P>Alzheimer's Disease Cooperative Study Clinical Global Impression of Changes</P>
</TD>
<TD>
<P>Is a seven point scale (1 indicates extreme improvement, 4 no change, 7 extreme worsening) which evaluates the amount of change in overall impairment compared with study baseline. The clinicians do not follow a structured interview to judge the changes</P>
</TD>
<TD>
<P>Schneider 1997</P>
</TD>
</TR>
<TR>
<TD>
<P>Behavioural disturbances</P>
</TD>
<TD>
<P>ABID</P>
</TD>
<TD>
<P>Agitated Behavior Inventory for Dementia</P>
</TD>
<TD>
<P>Is a 16 items instrument employed by caregivers of patients. Caregivers first rate behaviours according to frequency of occurrence and then the intensity of their own reaction to each problem behavior. Frequency score: 0 (did not occur) to 3 (occur daily or more often). Reaction score: 0 (not upsetting) to 4 (extreme upsetting).</P>
</TD>
<TD>
<P>Logsdon 1999</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>BPRS</P>
</TD>
<TD>
<P>Brief Psychiatric Rating Scale</P>
</TD>
<TD>
<P>Is a 18 items scale, evaluating mood and behaviour. The items are rated on a 7 points scale (not present to very severe)</P>
</TD>
<TD>
<P>Overall 1962</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>CERAD-BRSD</P>
</TD>
<TD>
<P>The Consortium To Establish a Registry of Alzheimer's Disease Behavioral Rating Scale for Dementia</P>
</TD>
<TD>
<P>It assesses behavioral symptoms in patients with AD. It covers domains of depression, psychotic features, irritability and agitation, psychotic features, vegetative features, apathy, aggression and affective lability. The items are rated on a 4 point scale to measure frequency. A high score indicates severe impairment</P>
</TD>
<TD>
<P>Tariot 1995</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>CMAI</P>
</TD>
<TD>
<P>Cohen-Mansfield Agitation Inventory</P>
</TD>
<TD>
<P>It assesses the frequency of 36 agitated behaviours rated on a seven point scale (1: never occurs, to 7: occurs several times an hour).It examines aggressive behavior, psychically nonaggressive behavior and verbally agitated behaviour.</P>
</TD>
<TD>
<P>Cohen-Mansfield 1996, Koss 1997</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>NPI</P>
</TD>
<TD>
<P>Neuropsychiatry Inventory</P>
</TD>
<TD>
<P>Is a 12 items instrument evaluating the frequency and severity of behavioral and neuropsychiatric symptoms (hallucinations, delusions, anxiety, agitation/aggression, depression/dysphoria, elation/euphoria, irritability, disinhibition, aberrant motor behavior, eating disorders and night-time behavior).The score ranging from 0 to 144, and a lower score indicates improvement.</P>
</TD>
<TD>
<P>Cummings 1994</P>
</TD>
</TR>
<TR>
<TD>
<P>Cognition</P>
</TD>
<TD>
<P>MMSE</P>
</TD>
<TD>
<P>Mini Mental State Examination</P>
</TD>
<TD>
<P>It was developed as a short test appropriate for elderly with dementia. It concentrates on the cognitive aspects of mental function. The five sections cover orientation, immediate recall, attention and calculation, delayed recall and language. The maximum score of 30 indicates no impairment.</P>
</TD>
<TD>
<P>Folstein 1975</P>
</TD>
</TR>
<TR>
<TD>
<P>Functional</P>
</TD>
<TD>
<P>PSM &amp; IADL</P>
</TD>
<TD>
<P>Physical Self Maintenance and Instrumental Activities of Daily Living</P>
</TD>
<TD>
<P>The scales assess physical self-maintenance and the ability to perform complex daily tasks: ability to use the telephone, transportation, shopping, food preparation, household tasks, laundry, responsibility for own medications and ability to mange finances.</P>
</TD>
<TD>
<P>Lawton 1969</P>
</TD>
</TR>
<TR>
<TD>
<P>Caregiver burden</P>
</TD>
<TD>
<P>RMBPC</P>
</TD>
<TD>
<P>Revised Memory and Behavior Problem Checklist</P>
</TD>
<TD>
<P>Is a 25 items checklist that assesses two scores of caregiver burden: Objective burden (number of items checked) and subjective burden (degree of distress). The positive scores indicate worsening</P>
</TD>
<TD>
<P>Teri 1992</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>SCB</P>
</TD>
<TD>
<P>Screen For Caregiver Burden</P>
</TD>
<TD>
<P>Caregivers rate 24 problem on two 5-point scales: frequency of problems and caregiver distress form each problem. A global score and three subscale scores are obtained for each scale (memory-related, depressive and disruptive)</P>
</TD>
<TD>
<P>Vitaliano 1991</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Parallel design. Trazodone (mean dose 200 +/- 75 mg/d) versus placebo for 16 weeks</NAME>
<DICH_OUTCOME CHI2="3.11969675300558" CI_END="1.7689196041253847" CI_START="0.5653168169247775" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="36" I2="35.89120487197485" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.24770809504757468" LOG_CI_START="-0.24770809504757468" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="1" P_CHI2="0.21016803849999144" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="108" WEIGHT="100.0" Z="0.0">
<NAME>ADCS Clinical Global Impression of Change</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.071775614146935E-32" CI_END="4.072322101919645" CI_START="0.5896437263363622" DF="0.0" EFFECT_SIZE="1.549586776859504" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="100.0" ID="CMP-001.01.01" LOG_CI_END="0.6098421213802628" LOG_CI_START="-0.22941031788568772" LOG_EFFECT_SIZE="0.19021590174728753" NO="1" P_CHI2="0.0" P_Z="0.3742995161072974" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="28.074245939675173" Z="0.888448574632862">
<NAME>ADCS-CGIC improved</NAME>
<DICH_DATA CI_END="4.072322101919646" CI_START="0.5896437263363623" EFFECT_SIZE="1.5495867768595042" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.609842121380263" LOG_CI_START="-0.2294103178856876" LOG_EFFECT_SIZE="0.19021590174728759" ORDER="312" O_E="0.0" SE="0.49298103719139447" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.24303030303030304" WEIGHT="28.074245939675173"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.337695259955983" CI_START="0.12337568012719927" DF="0.0" EFFECT_SIZE="0.40625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.12635718817519198" LOG_CI_START="-0.9087704402013304" LOG_EFFECT_SIZE="-0.3912066260130692" NO="2" P_CHI2="1.0" P_Z="0.13848361995607977" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="37.12296983758701" Z="1.4814615637331714">
<NAME>ADCS-CGIC no change</NAME>
<DICH_DATA CI_END="1.337695259955983" CI_START="0.12337568012719927" EFFECT_SIZE="0.40625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12635718817519198" LOG_CI_START="-0.9087704402013304" LOG_EFFECT_SIZE="-0.3912066260130692" ORDER="313" O_E="0.0" SE="0.6080390928727679" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.3697115384615385" WEIGHT="37.12296983758701"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.003359042880571" CI_START="0.47150539771688266" DF="0.0" EFFECT_SIZE="1.19" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.4776072539508681" LOG_CI_START="-0.32651333116580666" LOG_EFFECT_SIZE="0.07554696139253074" NO="3" P_CHI2="1.0" P_Z="0.7126671369150952" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="34.80278422273782" Z="0.36827641577988934">
<NAME>ADCS-CGIC worse</NAME>
<DICH_DATA CI_END="3.003359042880571" CI_START="0.47150539771688266" EFFECT_SIZE="1.19" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.4776072539508681" LOG_CI_START="-0.32651333116580666" LOG_EFFECT_SIZE="0.07554696139253074" ORDER="314" O_E="0.0" SE="0.4723444121586271" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.22310924369747898" WEIGHT="34.80278422273782"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.1278267323323018" CI_END="3.450674786236095" CI_START="-5.069836916794636" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8095810652792704" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.720696161883196" P_Q="0.720696161883196" P_Z="0.7095547862490634" Q="0.1278267323323018" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="0.37245409332599977">
<NAME>Agitated Behavior Inventory for Dementia (ABID) (change from baseline)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.615326795600854" CI_START="-9.515326795600854" DF="0.0" EFFECT_SIZE="-1.9499999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.6134251792671876" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="31.711441034686864" Z="0.5051903074531442">
<NAME>Frequency</NAME>
<CONT_DATA CI_END="5.615326795600854" CI_START="-9.515326795600854" EFFECT_SIZE="-1.9499999999999997" ESTIMABLE="YES" MEAN_1="-5.89" MEAN_2="-3.94" ORDER="315" SD_1="17.5" SD_2="15.44" SE="3.8599315371482263" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="31.711441034686864"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.875392168736136" CI_START="-5.435392168736136" DF="0.0" EFFECT_SIZE="-0.2799999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.9152255674065496" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="68.28855896531313" Z="0.10644969339078482">
<NAME>Reaction</NAME>
<CONT_DATA CI_END="4.875392168736136" CI_START="-5.435392168736136" EFFECT_SIZE="-0.2799999999999998" ESTIMABLE="YES" MEAN_1="-2.86" MEAN_2="-2.58" ORDER="316" SD_1="12.14" SD_2="10.28" SE="2.6303504602131524" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="68.28855896531313"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.220492793828164" CI_START="-2.860492793828162" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.180000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.206702261990934" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="1.262685472177846">
<NAME>Cohen-Mansfield Agitation Inventory (CMAI) (change from baseline)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.220492793828164" CI_START="-2.860492793828162" EFFECT_SIZE="5.180000000000001" ESTIMABLE="YES" MEAN_1="-0.76" MEAN_2="-5.94" ORDER="317" SD_1="16.46" SD_2="18.5" SE="4.102367623716836" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.748348559594472" CI_START="-12.088348559594472" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.67" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7533913957475973" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="0.3141706994596172">
<NAME>CERAD Behavioral Rating Scale for Dementia (BRSD) (change from baseline)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.748348559594472" CI_START="-12.088348559594472" EFFECT_SIZE="-1.67" ESTIMABLE="YES" MEAN_1="-6.95" MEAN_2="-5.28" ORDER="318" SD_1="20.87" SD_2="24.36" SE="5.315581634036684" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.16217460370837694" CI_START="-0.3821746037083769" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.42828837895461014" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="0.792124009227575">
<NAME>Revised Memory and Behavior Problem Checklist (RMBPC) (change from baseline)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.16217460370837694" CI_START="-0.3821746037083769" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.1" ORDER="319" SD_1="0.66" SD_2="0.52" SE="0.13886714544514872" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.1974494150694277" CI_START="-3.1825505849305724" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.69" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.02646989207612243" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="2.2192474863602487">
<NAME>Mini Mental State Eamination (MMSE) (change to baseline)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trazodone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1974494150694277" CI_START="-3.1825505849305724" EFFECT_SIZE="-1.69" ESTIMABLE="YES" MEAN_1="-1.97" MEAN_2="-0.28" ORDER="320" SD_1="3.15" SD_2="3.35" SE="0.7615193935723416" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.39140641528246783" CI_END="1.4521846367095979" CI_START="-0.3874009495193541" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5323918435951219" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.5315614291105732" P_Q="0.5315614291105732" P_Z="0.25660133985463984" Q="0.39140641528246783" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="1.1344607686869015">
<NAME>Lawton-Brody Activities of Daily Living (change from baseline)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4638742090169135" CI_START="-0.8438742090169133" DF="0.0" EFFECT_SIZE="0.31000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.5984962691897018" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="63.542320722111164" Z="0.5265641873779943">
<NAME>Physical activities of daily living</NAME>
<CONT_DATA CI_END="1.4638742090169135" CI_START="-0.8438742090169133" EFFECT_SIZE="0.31000000000000005" ESTIMABLE="YES" MEAN_1="1.62" MEAN_2="1.31" ORDER="321" SD_1="2.56" SD_2="2.47" SE="0.58872214903872" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="63.542320722111164"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.443335252054152" CI_START="-0.6033352520541521" DF="0.0" EFFECT_SIZE="0.92" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.23653317852361333" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="36.457679277888836" Z="1.1836966704114258">
<NAME>Instrumental Activities of Daily Living</NAME>
<CONT_DATA CI_END="2.443335252054152" CI_START="-0.6033352520541521" EFFECT_SIZE="0.92" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="0.89" ORDER="322" SD_1="3.32" SD_2="3.32" SE="0.777226145005738" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="36.457679277888836"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.040175317363592394" CI_END="1.8932324836297532" CI_START="-1.5302044448655667" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1815140193820933" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.841138285266144" P_Q="0.841138285266144" P_Z="0.8353550965912222" Q="0.040175317363592394" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="0.20783846649359677">
<NAME>Screen for Caregiver Burden (SCB)(change from baseline)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.959051592386758" CI_START="-1.7390515923867578" DF="0.0" EFFECT_SIZE="0.1100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="1.0" P_Z="0.9071784852400485" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="85.69719612358135" Z="0.11659817345665004">
<NAME>Objective</NAME>
<CONT_DATA CI_END="1.959051592386758" CI_START="-1.7390515923867578" EFFECT_SIZE="0.1100000000000001" ESTIMABLE="YES" MEAN_1="-1.14" MEAN_2="-1.25" ORDER="323" SD_1="4.04" SD_2="4.02" SE="0.9434110049836838" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="85.69719612358135"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.1360749732036926" CI_START="-3.916074973203692" DF="0.0" EFFECT_SIZE="0.6100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="1.0" P_Z="0.7916617283079642" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="14.302803876418647" Z="0.2641533862447637">
<NAME>Subjective</NAME>
<CONT_DATA CI_END="5.1360749732036926" CI_START="-3.916074973203692" EFFECT_SIZE="0.6100000000000001" ESTIMABLE="YES" MEAN_1="-1.97" MEAN_2="-2.58" ORDER="324" SD_1="10.06" SD_2="9.67" SE="2.309264358378416" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" WEIGHT="14.302803876418647"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.463869218464017" CI_END="1.3577159597504245" CI_START="0.5677336799697004" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8779641667987949" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.1328089230994467" LOG_CI_START="-0.2458553411257946" LOG_EFFECT_SIZE="-0.05652320901317395" METHOD="MH" NO="9" P_CHI2="0.48815750622721266" P_Q="0.0" P_Z="0.5584619323294062" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="407" TOTAL_2="396" WEIGHT="99.99999999999999" Z="0.5851275888582573">
<NAME>Frequency of adverse events at week 17</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Drooling</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="325" O_E="0.0" SE="0.0" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.426766443844372" CI_START="0.27662087821482184" DF="0.0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.8079925174313798" LOG_CI_START="-0.55811504421478" LOG_EFFECT_SIZE="0.12493873660829992" NO="2" P_CHI2="1.0" P_Z="0.7199684635764141" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="6.278737910258442" Z="0.3585009422407836">
<NAME>Parkinson gait</NAME>
<DICH_DATA CI_END="6.42676644384437" CI_START="0.2766208782148219" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8079925174313798" LOG_CI_START="-0.5581150442147799" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="326" O_E="0.0" SE="0.802458344052446" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.6439393939393938" WEIGHT="6.278737910258442"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.062571870809872" CI_START="0.4133955028888602" DF="0.0" EFFECT_SIZE="1.4466666666666668" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.7043712017288144" LOG_CI_START="-0.38363425214311786" LOG_EFFECT_SIZE="0.1603684747928483" NO="3" P_CHI2="1.0" P_Z="0.5634095107852262" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="9.513239257967337" Z="0.5777846677717113">
<NAME>Dry mouth</NAME>
<DICH_DATA CI_END="5.062571870809872" CI_START="0.4133955028888602" EFFECT_SIZE="1.4466666666666668" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7043712017288144" LOG_CI_START="-0.38363425214311786" LOG_EFFECT_SIZE="0.1603684747928483" ORDER="327" O_E="0.0" SE="0.6390997893182294" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.4084485407066052" WEIGHT="9.513239257967337"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.833580334335409" CI_START="0.608088699623965" DF="0.0" EFFECT_SIZE="2.566666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="1.0347720081006901" LOG_CI_START="-0.21603306719505133" LOG_EFFECT_SIZE="0.40936947045281946" NO="4" P_CHI2="1.0" P_Z="0.19951562606130357" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="5.707943554780402" Z="1.2829327835403157">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="10.833580334335409" CI_START="0.608088699623965" EFFECT_SIZE="2.566666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.0347720081006901" LOG_CI_START="-0.21603306719505133" LOG_EFFECT_SIZE="0.40936947045281946" ORDER="328" O_E="0.0" SE="0.734729092813698" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.5398268398268398" WEIGHT="5.707943554780402"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.092524710747516" CI_START="0.023599585608593193" DF="0.0" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.09.05" LOG_CI_END="0.32067059530468767" LOG_CI_START="-1.627095622855375" LOG_EFFECT_SIZE="-0.6532125137753437" NO="5" P_CHI2="1.0" P_Z="0.18864220663157985" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="9.132709687648642" Z="1.3146064340924286">
<NAME>Akathesia</NAME>
<DICH_DATA CI_END="2.092524710747516" CI_START="0.023599585608593193" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32067059530468767" LOG_CI_START="-1.627095622855375" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="329" O_E="0.0" SE="1.1441275181454984" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="1.3090277777777777" WEIGHT="9.132709687648642"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4809651499245344" CI_START="0.12062779536040134" DF="0.0" EFFECT_SIZE="0.5470588235294118" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.09.06" LOG_CI_END="0.39462066378781974" LOG_CI_START="-0.9185526094364972" LOG_EFFECT_SIZE="-0.26196597282433876" NO="6" P_CHI2="1.0" P_Z="0.4342207366037856" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="10.781671159029647" Z="0.78198952473349">
<NAME>Rigidity</NAME>
<DICH_DATA CI_END="2.4809651499245344" CI_START="0.12062779536040134" EFFECT_SIZE="0.5470588235294118" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.39462066378781974" LOG_CI_START="-0.9185526094364972" LOG_EFFECT_SIZE="-0.26196597282433876" ORDER="330" O_E="0.0" SE="0.771364481004502" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.5950031625553447" WEIGHT="10.781671159029647"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4352054356344803" CI_START="0.004063115156820541" DF="0.0" EFFECT_SIZE="0.07636363636363637" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-001.09.07" LOG_CI_END="0.15691407053111364" LOG_CI_START="-2.3911408687238005" LOG_EFFECT_SIZE="-1.1171133990963433" NO="7" P_CHI2="1.0" P_Z="0.08569317870335112" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="12.731885206912953" Z="1.7185673630068534">
<NAME>Dyskinesia</NAME>
<DICH_DATA CI_END="1.4352054356344794" CI_START="0.004063115156820544" EFFECT_SIZE="0.07636363636363637" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.15691407053111336" LOG_CI_START="-2.3911408687238" LOG_EFFECT_SIZE="-1.1171133990963433" ORDER="331" O_E="0.0" SE="1.4967400843937066" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="2.24023088023088" WEIGHT="12.731885206912953"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.062571870809872" CI_START="0.4133955028888602" DF="0.0" EFFECT_SIZE="1.4466666666666668" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.09.08" LOG_CI_END="0.7043712017288144" LOG_CI_START="-0.38363425214311786" LOG_EFFECT_SIZE="0.1603684747928483" NO="8" P_CHI2="1.0" P_Z="0.5634095107852262" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="9.513239257967337" Z="0.5777846677717113">
<NAME>Drowsiness</NAME>
<DICH_DATA CI_END="5.062571870809872" CI_START="0.4133955028888602" EFFECT_SIZE="1.4466666666666668" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7043712017288144" LOG_CI_START="-0.38363425214311786" LOG_EFFECT_SIZE="0.1603684747928483" ORDER="332" O_E="0.0" SE="0.6390997893182294" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.4084485407066052" WEIGHT="9.513239257967337"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.100185899498715" CI_START="0.3014156165911017" DF="0.0" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-001.09.09" LOG_CI_END="0.4913877366426056" LOG_CI_START="-0.5208342502840183" LOG_EFFECT_SIZE="-0.014723256820706345" NO="9" P_CHI2="1.0" P_Z="0.9545314601785293" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="13.31853496115427" Z="0.05701724221845023">
<NAME>Bradykinesia</NAME>
<DICH_DATA CI_END="3.100185899498715" CI_START="0.3014156165911017" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4913877366426056" LOG_CI_START="-0.5208342502840183" LOG_EFFECT_SIZE="-0.014723256820706345" ORDER="333" O_E="0.0" SE="0.5945842057003438" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.3535303776683087" WEIGHT="13.31853496115427"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0573251596543045" CI_START="0.184728477824289" DF="0.0" EFFECT_SIZE="0.7515151515151515" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.09.10" LOG_CI_END="0.485341630264827" LOG_CI_START="-0.7334661483681696" LOG_EFFECT_SIZE="-0.12406225905167124" NO="10" P_CHI2="1.0" P_Z="0.6898866666976524" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="10.46456318376407" Z="0.3990088738269742">
<NAME>Tremor</NAME>
<DICH_DATA CI_END="3.0573251596543045" CI_START="0.184728477824289" EFFECT_SIZE="0.7515151515151515" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.485341630264827" LOG_CI_START="-0.7334661483681696" LOG_EFFECT_SIZE="-0.12406225905167124" ORDER="334" O_E="0.0" SE="0.7159337223648286" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.5125610948191593" WEIGHT="10.46456318376407"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.357392549448413" CI_START="0.15581174985239218" DF="0.0" EFFECT_SIZE="0.6060606060606061" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-001.09.11" LOG_CI_END="0.37243190660761794" LOG_CI_START="-0.8073997950354305" LOG_EFFECT_SIZE="-0.21748394421390624" NO="11" P_CHI2="1.0" P_Z="0.46993869146598943" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="36" WEIGHT="12.557475820516885" Z="0.722578817438722">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="2.3573925494484125" CI_START="0.1558117498523922" EFFECT_SIZE="0.6060606060606061" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3724319066076179" LOG_CI_START="-0.8073997950354304" LOG_EFFECT_SIZE="-0.21748394421390624" ORDER="335" O_E="0.0" SE="0.6930389818062402" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.48030303030303023" WEIGHT="12.557475820516885"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9307940361160925" CI_START="0.4060615075514499" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.46698529912037756" LOG_CI_START="-0.39140817734157807" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.8629935789814235" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="0.17256472795225153">
<NAME>Dropouts by endpoint</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9307940361160925" CI_START="0.4060615075514499" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.46698529912037756" LOG_CI_START="-0.39140817734157807" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="336" O_E="0.0" SE="0.50422457718999" STUDY_ID="STD-Teri-2000" TOTAL_1="37" TOTAL_2="36" VAR="0.2542424242424242" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Cross-over design. Trazodone (range 50 to 300 mg/d) versus placebo for 6 weeks</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.745402698055791" CI_START="-13.345402698055786" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7999999999999972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9005364332005681" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.12498372713655757">
<NAME>Neuropsychiatric Inventory (NPI)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.745402698055791" CI_START="-13.345402698055786" EFFECT_SIZE="-0.7999999999999972" ESTIMABLE="YES" MEAN_1="55.1" MEAN_2="55.9" ORDER="337" SD_1="16.4" SD_2="19.2" SE="6.400833279086924" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3800762096105389" CI_START="-1.380076209610539" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.26548541004643" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.1135194674830486">
<NAME>Clinical Global impression Improvement (CGI-I)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3800762096105389" CI_START="-1.380076209610539" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.3" ORDER="338" SD_1="1.2" SD_2="1.3" SE="0.44902672526253934" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.778312881710233" CI_START="-5.978312881710229" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999787" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9734016318956178" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.03334228755734047">
<NAME>Mini-Mental State Examination (MMSE)</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.778312881710233" CI_START="-5.978312881710229" EFFECT_SIZE="-0.09999999999999787" ESTIMABLE="YES" MEAN_1="20.8" MEAN_2="20.9" ORDER="339" SD_1="6.7" SD_2="9.8" SE="2.9991943362621014" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1591030836993108" CI_END="3.6889549059992945" CI_START="0.16748846232234482" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7860390478737631" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.5669033464180826" LOG_CI_START="-0.7760151045812966" LOG_EFFECT_SIZE="-0.104555879081607" METHOD="MH" NO="4" P_CHI2="0.5601497027592746" P_Q="0.0" P_Z="0.7602179140174637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="48" WEIGHT="100.0" Z="0.3051946411479744">
<NAME>Number of participants with a side effect</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.165793502971919" CI_START="0.04054628165531325" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.7899889757875797" LOG_CI_START="-1.392048967115542" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.5886549921562676" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="49.42497994116074" Z="0.5407861505677283">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="6.165793502971916" CI_START="0.040546281655313265" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7899889757875794" LOG_CI_START="-1.392048967115542" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="340" O_E="0.0" SE="1.2817398889233114" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" VAR="1.6428571428571428" WEIGHT="49.42497994116074"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="90.49252417518257" CI_START="0.12878393501976268" DF="0.0" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" NO="2" P_CHI2="1.0" P_Z="0.4627911526675562" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="12.021930997592941" Z="0.734258596203755">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="90.49252417518257" CI_START="0.12878393501976268" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" ORDER="341" O_E="0.0" SE="1.6721956358375376" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" VAR="2.7962382445141065" WEIGHT="12.021930997592941"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.83317793356023" CI_START="0.012578837644486076" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.9461169788559071" LOG_CI_START="-1.900359488295232" LOG_EFFECT_SIZE="-0.4771212547196625" NO="3" P_CHI2="1.0" P_Z="0.5111479607368596" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="38.553089061246325" Z="0.6570512606029192">
<NAME>Cold extremities</NAME>
<DICH_DATA CI_END="8.83317793356023" CI_START="0.012578837644486076" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9461169788559071" LOG_CI_START="-1.900359488295232" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="342" O_E="0.0" SE="1.6720343670903366" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" VAR="2.7956989247311825" WEIGHT="38.553089061246325"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.647664776675484" CI_START="0.5145777045037015" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.3550234281197853" LOG_CI_START="-0.2885490347225978" LOG_EFFECT_SIZE="0.5332371966985938" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.2034537410224565" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="48" WEIGHT="99.99999999999999" Z="1.271773194519104">
<NAME>Drop-outs in the first treatment period</NAME>
<GROUP_LABEL_1>Trazodone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="90.49252417518257" CI_START="0.12878393501976268" DF="0.0" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" NO="1" P_CHI2="1.0" P_Z="0.4627911526675562" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="33.33333333333333" Z="0.734258596203755">
<NAME>drop-out due to adverse event (hypotension with syncope)</NAME>
<DICH_DATA CI_END="90.49252417518257" CI_START="0.12878393501976268" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" ORDER="343" O_E="0.0" SE="1.6721956358375376" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" VAR="2.7962382445141065" WEIGHT="33.33333333333333"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="90.49252417518257" CI_START="0.12878393501976268" DF="0.0" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" NO="2" P_CHI2="1.0" P_Z="0.4627911526675562" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="33.33333333333333" Z="0.734258596203755">
<NAME>drop-out due to lack of efficacy (agitation)</NAME>
<DICH_DATA CI_END="90.49252417518257" CI_START="0.12878393501976268" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" ORDER="344" O_E="0.0" SE="1.6721956358375376" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" VAR="2.7962382445141065" WEIGHT="33.33333333333333"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="90.49252417518257" CI_START="0.12878393501976268" DF="0.0" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" NO="3" P_CHI2="1.0" P_Z="0.4627911526675562" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="33.33333333333333" Z="0.734258596203755">
<NAME>drop out due non elective-surgery</NAME>
<DICH_DATA CI_END="90.49252417518257" CI_START="0.12878393501976268" EFFECT_SIZE="3.413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9566127024806532" LOG_CI_START="-0.8901383090834654" LOG_EFFECT_SIZE="0.5332371966985938" ORDER="345" O_E="0.0" SE="1.6721956358375376" STUDY_ID="STD-Lebert-2004" TOTAL_1="15" TOTAL_2="16" VAR="2.7962382445141065" WEIGHT="33.33333333333333"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>